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ABSTRACT

Methods are described that bias cells, such as potent and
multipotent stem cells, by transfection with a nucleic acid
sequence, to differentiate to a desired end-stage cell or a cell
having characteristics of a desired end-stage cell. In particular
embodiments, human neural stem cells are transfected with
vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results
in a greater percentage of resultant transformed cells, or their
progeny, differentiating into a desired end-stage cell or a cell
having characteristics of a desired end-stage cell.
11 Claims, 17 Drawing Sheets
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METHODS AND PRODUCTS FOR BIASING
CELLULAR DEVELOPMENT

One advantage of use of mulitpotent and more committed
cells further along in differentiation, compared to pluripotent
embryonic stem cells, is the reduced possibility that some
cells introduced into an organism from such source will form
a tumor (Stem Cell Biology, Marshak et al., p. 407). However,
a disadvantage of cells such as cell types developed from
multipotent stem cells, for instance, embryonic progenitor
cells, is that they are not amenable to ongoing cell culture. For
instance, embryonic neural progenitor cells, which are able to
differentiate into neurons and astrocytes, are reported to survive only one to two months in a cell culture.
Generally, it is known in the art that the lack of certain
factors critical to differentiation will result in no or improper
differentiation of a stem cell. Researchers also have demonstrated that certain factors may be added to a culture system
comprising stem cells, such as embryonic stem cells, so that
differentiation to a desired, stable end-stage differentiated
cell proceeds. It also is known in the art to introduce and
express a transcription factor gene, Nurrl, into embryonic
stem cells, and then process the cells through a five-step
differentiation method (Kim, Jong-Hoon et al., Dopamine
Neurons Derived from Embryonic Stem Cells Function in an
Animal Model of Parkinson's Disease, Nature, 418:50-56
(2002)), resulting in differentiated cells having features of
dopaminergic cells. However, the starting cell for this was an
embryonic stem cell, and the differentiation process through
to a cell having the features of a dopaminergic neuron,
requires substantial effort that includes the addition and control of endogenous factors. In addition, because the starting
cell is an early-stage embryonic stem cell having pluripotency, there is a relatively higher risk that some cells
implanted from this source will become tumerogenic.
Also, without being bound to a particular theory, it is
believed that to the extent a particular method of differentiation results in a greater percentage of cells that are dedicated
or predetermined to differentiate to a desired functional cell
type (i.e., a cholinergic neuron), this reduces the chance of
tumor formation after introduction of cells derived from such
method. As disclosed herein, embodiments of the present
method that utilize multipotent stem cells as the starting
material provide an increased percentage of cells predisposed
(i.e., biased) to or differentiated to a desired cell type. This is
believed to provide for reduced risk of tumor formation
equivalent to or superior to the use of more differentiated cells
such as NRPs.
There are many possible applications for methods, compositions, and systems that provide for improved differentiation
of stem cells to a desired functional, differentiated cell. For
example, not to be limiting, millions of people suffer from
deafness and balance defects caused by damage to inner ear
hair cells (IEHCs ), the primary sensory receptor cells for the
auditory and vestibular system after exposure to loud noises,
antibiotics, or antitumor drugs. Since IEHCs rarely regenerate in mammals, any damage to these organs is almost irreversible, precludes any recovery from hearing loss, and
results in potentially devastating consequences. Current
therapies utilizing artificial cochlear implants or hearing aids
may partially improve but not sufficiently restore hearing.
Therefore, cell therapy to replace the damaged IEHC may be
one of the most promising venues today. In the past, IEHC
production from progenitor cells from the vestibular sensory
epithelium of the bullfrog {Cristobal, 1998 #28} and possible
existence of IEHC progenitors in mammalian cochlea sensory epithelia {Kojima, 2004 #29} has been reported. However limited quantity of IEHC progenitor prevents clinical

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claims priority to U.S. Ser. No. 60/621,
483 filed Oct. 22, 2004, which is hereby incorporated in its
entirety.
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FIELD OF INVENTION
The present invention is directed to methods and systems
directed to altering the differentiation of a cell, more particularly to biasing a multipotent stem cell by transfecting the cell
with a nucleic acid sequence comprising a desired gene, the
gene being expressed so that the cell, or its progeny, differentiate to a desired end-stage cell.
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BACKGROUND
Proper cellular function and differentiation depends on
intrinsic signals and extracellular environmental cues. These
signals and cues vary over time and location in a developing
organism (i.e., during embryogenesis ), and remain important
in developing and differentiating cells during post-natal
growth and in a mature adult organism. Thus, in a general
sense, the interplay of the dynamically changing set of intracellular dynamics (such as manifested by intrinsic chemical
signaling and control of gene expression) and environmental
influences (such as signals from adjacent cells) determine
cellular activity. The cellular activity so determined is known
to include cell migration, cell differentiation, and the manner
a cell interacts with surrounding cells.
The use of stem cells and stem-cell-like cells of various
types for cell replacement therapies, and for other cell-introduction-based therapies, is being actively pursued by a number of researchers. Embryonic stems cells from a blastocyst
stage are frequently touted for their pluripotency-that is,
their ability to differentiate into all cell types of the developing organism. Later-stage embryonic stem cells, and certain
cells from generative areas of an adult organism, are identified as more specialized, multipotent stem cells. These cells
include cells that are able to give rise to a succession of a more
limited subset of mature end-stage differentiated cells of particular types or categories, such as hematopoietic, mesenchymal, or neuroectodermal end-stage differentiated cells. For
example, a multipotent neural stem cell may give rise to one
or more neuron cell types (i.e., cholinergic neuron, dopaminergic neuron, GABAergic neurons), which includes their specific cell classes (i.e., a basket cell or a chandelier cell for
GABAergic neurons), and to non-neuron glial cells, such as
astrocytes and dendrocytes.
Further along the path of differentiation are cells derived
from multipotent stem cells. For example, derivatives of a
localized, non-migrating neuroectodermal type stem cell may
migrate but, compared to their multipotent parent, have more
limited abilities to self-renew and to differentiate (See Stem
Cell Biology, Marshak, Gardner & Gottlieb, Cold Spring
Harbor Laboratory Press, 2001, particularly Chapter 18, p.
407). Some of these cells are referred to a neuron-restricted
precursors ("NRPs"), based on their ability, under appropriate conditions, to differentiate into neurons. There is evidence
that these NRPs have different subclasses, although this may
reflect different characteristics of localized multipotent stem
cells (Stem Cell Biology, Marshak et al., pp 418-419).
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application of this type of cell to treat deafness. Thus novel
technology to produce IEHCs from other cell sources is
needed.
While stem cells are known to be the building blocks
responsible for producing all of a body's cells, the specific
differentiation process towards to IEHC linage is not clear.
Embryonic stem cells transplanted into the inner ear of adult
mice or embryonic chickens did not differentiate into IEHCs
{Sakamoto, 2004 #19}. Neural stem cells (NSCs) grafted into
the modiolus of cisplatin-treated cochleae of mice only differentiated into glial or neuronal cells within the cochleae
{Tamura, 2004 #18}. In order to produce IEHCs from these
stem cells, modification or direction of the cell fate decision
may be needed.
Another possible application for methods, compositions,
and systems of the present invention is biasing Human Neural
Stem Cells ("HNSCs") to differentiate to cholinergic neurons, or to cells having characteristics of cholinergic neurons.
Such biasing would provide for an improved percentage of
such stem cells in a culture vessel to differentiate to this
desired end-stage nerve cell. Improvements to the percentage
of cells that are known to be biased to differentiate to this
end-stage neuron cell, or to cells having characteristics of a
cholinergic neuron, may lead to improvements both in
research and treatment technologies for diseases and conditions that involve degeneration or loss of function of cholinergic neurons. Alzheimer's disease is one example of a
malady known to be associated with degeneration of the
long-projecting axons of cholinergic neurons.
Thus, there is a need in the art to improve the compositions,
methods and systems that provide biased and/or differentiated cells from stem cells or stem-cell-like cells. More particularly, a need exists to obtain a higher percentage of desired
cells from a pre-implantation cell culture, such as starting
from multipotent stem cells and obtaining a higher percentage of cells committed to differentiate to a specified type of
functional nerve cell, such as cholinergic neurons or inner ear
hair cells. The present invention addresses these needs.

FIG. 12: Differentiated HNSCs/Lhx8 in co-culture with
LA-N-2 cells. Cells were double-immunofluorescence
stained with (a) ~III-tubulin (red) and (b) ChAT (green),
markers for colinergic neurons (c) two localization of ~III
tubulin and ChAT. Blue signal is a counter staining for nuclei
by DAPI.
FIG. 13: Differentiated HNSCs/LHX8 in co-culture with
law and 2 cells. Cells were double immunofluorescence
stained with (a) ~III-tubulin (green) and (b) CHAT (red),
markers for colinergic neurons (c) co-localization of ~III
tubulin and CHAT. (20 x magnification) blue signal is a
counter staining for nuclei for DAPI. (d) insert for nonOspecific staining for c ~III-tubulin and CHAT, respectively.
FIG. 14 Differentiated HNSCs/Lhx8 in co-culture with
LA-N-2 cells. A) ~III-tubulin (green) and b) ChAT (red),
markers for cholinergic neurons, c) co-localization of ~III
tubulin & ChAT. Blue signal is a counter staining for nuclei by
DAPI (40 x magnification).
FIG. 15 Differentiated non-transfected HNSCs in co-culture with LA-N-2 cells. Cells were double-immunofluorescence stained with ~III-tubulin (green) and nuclei counter
staining by DAPI (Blue). No Chat-positive neurons were
observed. (a-b) 10 x and (c) 20 x magnification, respectively.
FIG. 16 Differentiated non-transfected HNSCs in co-culture with LA-N-2 cells. Cells were double-immunofluorescense stained with (a-b) ~III-tubulin (green) and (c)GFAP
(red) markers for neurons and astrocytes, respectively. Blue
signal is a counter staining for nuclei by DAPI.
FIG. 17 shows that transfection with Nkx2-5 (SEQ ID NO:
12) biases the differentiation toward the development of cardiac cells. Red=human specific Troponin I, Green=Human
cells. Following transfection, multipotent stem cells were
cocultured with rat cardiomyocytes that provide environmental signals to allow the transfected cells to develop properly.
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OF THE INVENTION
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BRIEF DESCRIPTION OF THE FIGURES
FIGS. 1-17 are appended hereto, are part of the specification, and are described herein and/or on the figures themselves.
FIG. 3Math1 full lengthMRNA was amplified by RT-PCR
and digested with Apai, which cuts position 441 of
HathlORF. Expecting fragment sizes are 441 by and 624 bp.
M: 100 bp marker; 5, 6, without transfection (control); 7, 8:
transfected with mammarian expression vector containing
Hath2.
FIG. 9: Phase contrast micrographs of LA-N2 cells. FIG.
9a: LA-N2cells grow in clusters as adherent fibroblasts-like
cells, occasionally cells extend short processes and form neuronal-like networks. FIG. 9b: LA-N2 cells treated with 10- 6
µM retinoic acid.
FIG. 10: Lhx8 expression in the LA-N-2 and HNSCs cells.
FIG. lOa: Shows gene expression with RT-PCR analysis of
LA-N-2 cells treated with ten µM RA showed an increased
expression ofLhx8 (394 bp) and ChAT (splice variants -600
and 400 bp, respectively, compared with non-treated cells.
FIG. lOb: represents RT-PCR analysis ofLhx8 expression in
HNSCs 48 hours post-transfection.
FIG. 11: In vitro differentiation of Lhx8-transfected
HNSCs. HNXCs tranfected with Lhx8 (a) in co-culture with
LA-N-2 cells and serum-free conditions differentiated mostly
neurons with long extended processes after 10-14 days (b-f).
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In reviewing the detailed disclosure which follows, and the
specification more generally, it should be borne in mind that
all patents, patent applications, patent publications, technical
publications, scientific publications, and other references referenced herein are hereby incorporated by reference in this
application in order to more fully describe the state of the art
to which the present invention pertains.
Reference to particular buffers, media, reagents, cells, culture conditions and the like, or to some subclass of same, is
not intended to be limiting, but should be read to include all
such related materials that one of ordinary skill in the art
would recognize as being of interest or value in the particular
context in which that discussion is presented. For example, it
is often possible to substitute one buffer system or culture
medium for another, such that a different but known way is
used to achieve the same goals as those to which the use of a
suggested method, material or composition is directed.
It is important to an understanding of the present invention
to note that all technical and scientific terms used herein,
unless defined herein, are intended to have the same meaning
as commonly understood by one of ordinary skill in the art.
The techniques employed herein are also those that are known
to one of ordinary skill in the art, unless stated otherwise. For
purposes of more clearly facilitating an understanding the
invention as disclosed and claimed herein, the following definitions are provided.
Definitions:
Stem cells are undifferentiated cells that exist in many
tissues of embryos and adult organisms. In embryos, blasto-

US 8,080,420 B2
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cyst stem cells are the source of cells that differentiate to form
the specialized tissues and organs of the developing fetus. In
adults, specialized stem cells in individual tissues are the
source of new cells, replacing cells lost through cell death due
to natural attrition, disease, or injury. Stem cells may be used
as substrates for producing healthy tissue where a disease,
disorder, or abnormal physical state has destroyed or damaged normal tissue.
Five defining characteristics of stem cells have been
advanced (from Weiss et al., 1996). That is, stems cells generally are recognized as having the ability to:
1. Proliferate: Stem cells are capable of dividing to produce
daughter cells.
2. Exhibit self-maintenance or renewal over the lifetime of
the organism: Stem cells are capable ofreproducing by
dividing symmetrically or asymmetrically to produce
new stem cells. Symmetric division occurs when one
stem cell divides into two daughter stem cells. Asymmetric division occurs when one stem cell forms one
new stem cell and one progenitor cell. Symmetric division is a source of renewal of stem cells. This permits
stem cells to maintain a consistent level of stem cells in
an embryo or adult mammal.
3. Generate large number of progeny: Stem cells may produce a large number of progeny through the transient
amplification of a population of progenitor cells.
4. Retain their multilineage potential over time: The various lines of stem cells collectively are the ultimate
source of differentiated tissue cells, so they retain their
ability to produce multiple types of progenitor cells,
which in turn develop into specialized tissue cells.
5. Generate new cells in response to injury or disease: This
is essential in tissues which have a high turnover rate or
which are more likely to be subject to injury or disease,
such as the epithelium or blood cells.
Thus, key features of stem cells include their capability of
self-renewal, and their capability to differentiate into a range
of end-stage differentiated tissue cells.
By "neural stem cell" (NSC) is meant a cell that (i) has the
potential of differentiating into at least two cell types selected
from a neuron, an astrocyte, and an oligodendrocyte, and (ii)
exhibits self-renewal, meaning that at a cell division, at least
one of the two daughter cells will also be a stem cell. Generally, the non-stem cell progeny of a single NSC are capable of
differentiating into neurons, astrocytes, Schwarm cells, and
oligodendrocytes. Hence, a stem cell such as a neural stem
cell is considered "multipotent" because its progeny have
multiple differentiative pathways. Under certain conditions
an NSC also may have the potential to differentiate as another
non-neuronal cell type (e.g., a skin cell, a hematopoietic cell,
a smooth muscle cell, a cardiac muscle cell, a skeletal muscle
cell, a bone cell, a cartilage cell, a pancreatic cell or an
adipocyte ).
By "Human Neural Stem Cell" ("HNSC") is meant a neural stem cell of human origin. A HNSC may be of fetal origin,
or adult origin from a neural source, or may be derived from
other cell sources, such as by de-differentiating a cell of
mesenchymal origin. As to the latter, for example see U.S.
application serial No. 2003/0219898, which is incorporated
by reference, inter alia, specifically for this teaching. HNSCs
of the invention are distinguished from natural HNSCs by
their adaptation for proliferation, migration and differentiation in mammalian host tissue when introduced thereto.
By a "population of cells" is meant a collection of at least
ten cells. A population may consist of at least twenty cells, or
of at least one hundred cells, or of at least one thousand or
even one million cells. Because the NSCs of the present

invention exhibit a capacity for self-renewal, they can be
expanded in culture to produce a collection of large numbers
of cells.
By "potent cell" is meant a stem cell that has the capability
to differentiate into a number of different types of end-stage
cell types, and to self-renew, and may include stem cells
classified as pluripotent, multipotent, or cells more differentiated than multipotent (i.e., a dedicated progenitor) under
different stem cell classification schemes.
By "a presumptive end-stage cell" is meant a cell that has
acquired characteristics of a desired end-stage cell type, but
which has not been conclusively identified as being the
desired end-stage cell. A presumptive end-stage cell possesses at least two, and often more, morphological and/or
molecularphenotypic properties of the desired end-stage cell.
The practice of the present invention will employ, unless
otherwise indicated, conventional techniques of cell biology,
cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within
the skill of the art. Such techniques are explained fully in the
literature. See, for example, Molecular Cloning A Laboratory
Manual, 3rd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold
Spring Harbor Laboratory Press: 2001); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide
Synthesis (M. J. Gait ed., 1984); Mullis et al., U.S. Pat. No.
4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J.
Higgins eds. 1984); Transcription And Translation (B. D.
Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells
(R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells
And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide
To Molecular Cloning (1984 ); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors
For Mammalian Cells (J. H. MillerandM. P. Calos eds., 1987,
Cold Spring Harbor Laboratory); Methods In Enzymology,
Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods
In Cell And Molecular Biology (Mayer and Walker, eds.,
Academic Press, London, 1987); Handbook Of Experimental
Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell,
eds., 1986); Manipulating the Mouse Embryo, (Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).
U.S. Patent Application Nos. 2003/0219898, 2003/
0148513, and 2003/0139410 are incorporated by reference to
the extent they are not inconsistent with the teachings herein.
The first two of these patent applications describe multiple
uses of increased potency cells obtained from the taught
methods, and in particular, the implantation of stem cells for
different therapeutic treatments of neurological trauma and
degenerative conditions. The third patent application is
directed to the use of certain compounds to stimulate proliferation and migration of stem cells. Those skilled in the art
will readily appreciate that the cells of the present invention
could be obtained, or their effectiveness enhanced, by combining with the teachings of the aforementioned patent applications, without undue experimentation.
The present invention is directed to compositions, methods
and systems that provide for increased percentage of neural
stem cells and other multipotent or potent stem cells to
become committed, or predisposed, to differentiate to a
desired end-stage differentiated nerve cell. More particularly,
the present invention utilizes the introduction into such a stem
cell of a nucleic acid sequence comprising a developmental
control gene. A developmental control gene as used in the
present invention may encode a transcription factor, cellsurface molecule, or a secreted signal molecule (See Fundamental Neuroscience, Zigmond, Bloom, Landis, Roberts and
Squire, Academic Press, 1999, Chapter 15). Examples below
provide details of the introduction of three transcription factor
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type genes-Lhx8 and Gbxl that improve differentiation of
human neural stem cells (HNSCs) to cells having characteristics of cholinergic neurons, and Hathl that improves differentiation ofHNSCs to cells having characteristics of inner ear
hair cells (IEHCs ). The effectiveness of these single-gene
introductions to such cells is unexpected and surprising in
view of the subtlety and complexity of differentiation of
multipotent stem cells to cells such as neural cells like cholinergic nerve cells and inner ear hair cells. Other development control genes having capability to achieve similar
desired results are disclosed.
The present invention advances the art by demonstrating
the utility, in multipotent stem cells, of introducing for
expression a nucleic acid sequence that comprises a desired
developmental control gene. One example of such introducing is transfection by a vector comprising the nucleic acid
sequence. After such introducing, the introduced developmental control gene is expressed in the cell (or its progeny), at
least transiently. By so altering a multipotent stem cell, the
present invention provides for more consistent differentiation
to a desired functional cell type, such as a cholinergeric nerve
cell. In doing so, this is believed to reduce known risks ofthis
type of cell transplantation, such as the risk of tumor growth
upon implantation of cells from pluripotent embryonic cell
cultures.
Thus, in some embodiments the present invention is
directed to biasing a multipotent cell such that the cell
becomes programmed, or biased, to differentiate into a
desired cell type under appropriate external conditions. This
is done in some embodiments so that in a pre-implantation
cell culture a greater percentage of cells are either pre-disposed to differentiate to and/or do differentiate to a desired
cell type. More particularly, in certain embodiments of this
biasing, the cell is transformed so it expresses a certain factor
that biases the same cells to differentiate to a desired cell type
upon a later implantation to a particular tissue in a living
organism. In such embodiments, this improves a differentiation ratio so that a higher percentage of cells introduced into
a particular cell medium, a tissue culture, or a living organism
in a particular location differentiate into the end-stage differentiated cell type that is desired. Without being bound to a
particular theory, this is believed to increase the probability of
success and overall effectiveness, and to decrease the risks
associated with implantation of cells obtained from embryonic stem cells or embryonic-cell-like cells.
While not meant to be limiting as to the type of nucleic acid
sequence introduced, examples herein utilize introduction to
a cell of a nucleic acid sequence comprising a homeobox
gene. This is a gene group that includes a number of known
developmental control genes. A homeobox gene is a gene
containing an approximately 180-base-pair segment (the
"homeo box") that encodes a protein domain involved in binding to (and thus regulating the expression of) DNA. The
homeobox segment is remarkably similar in many genes with
different functions. However, specific homeobox genes are
known to operate at different stages, and in different tissue
environments, to yield very different specific results. For
example, in relatively early embryological development in
the vertebrate embryo, expression of genes of the Hox family
ofhomeobox genes appears to affect development of the brain
based on position along the anterior/posterior axis. This is
believed to control identity and phenotypic specializations of
individual rhombomeres. (Fundamental Neuroscience, Zigmond et al., p. 435). Later in development, LIM homeobox
gene expression is associated with the projection pattern of
developing primary motor neurons, and more generally,
expression of a particular combination of LIM homeobox

genes appears to be related to motor neuron subtype identity
and to targeting specificity (Fundamental Neuroscience, Zigmond et al., p. 507). Also, some LIM homeobox genes appear
to affect developmental progression, rather than fate, of
motor neurons, which suggests a role of cell-to-cell signaling
in the embryo to fully effectuate the differentiation in vivo
(Fundamental Neuroscience, Zigmond et al., pp. 443-444).
These highly specialized and variable roles for homeobox
genes in general, and for LIM family homeobox genes more
particularly, demonstrate the subtle, specific, and highly variable effects that these genes may have on cell and tissue
development and differentiation.
Further with regard to function ofhomeobox genes, these
genes encode transcriptional regulators that play critical roles
in a variety of developmental processes. Although the genetic
and developmental mechanisms that control the formation of
forebrain cholinergic neurons are just beginning to be elucidated, it is known that the vast majority offorebrain cholinergic neurons derive from a region of the subcortical telencephalon that expresses the Nkx2-1 homeobox gene.
It has recently been reported that Nkx2-1 appears to
specify the development of the basal telencephalon by positively regulating transcription factors such as the LIM-homeobox genes Lhx8 (also known as L3 or Lhx7) and Gbxl,
which are associated with the development of cholinergic
neurons in the basal forebrain (Zhao et al., 2003; Asbreuk et
al., 2002, Waters et al., 2003).
In the spinal cord, IsLl, Lhxl, Lhx3 and Lhx4 have been
shown to be important for the development of spinal cord
cholinergic neurons (Pfaff et al., 1996; Sharma et al., 1998;
Kania et al., 2000). Given that the spinal cord cholinergic
neurons are reported to require multiple LIM-homeobox
genes for their development, it is expected that Lhx8 is not the
only LIM-homeobox gene that is required in generating
telencephalic cholinergic neurons. Other candidates are Lhx6
and IsLl, which are also expressed in the basal telencephalon
(Marin et al., 2000). Also, it is suggested that Dlxl/2 and
Mash, though not directly regulating Lhx8, participate in
controlling the number of cholinergic neurons that are formed
in the telencephalon (Marin et al., 2000).
Thus, at a minimum, developmental control genes that may
be used in the present invention to transfect cells to bias those
cells (or their progeny) to differentiate to a desired end-stage
cell type, here that cell type being cholinergic neurons,
include, but are not limited to Lhx8, Gbxl, Lhx6, IsLl,
Dlxl/2 and Mash.
The Human Neural Stem Cells (HNSCs ), such as discussed
in the examples below, are obtained from cultures that were
started from clones obtained from human fetal brain tissue.
One lineage was obtained by isolating individual cells from
neurospheres of a fetal brain tissue sample obtained from
Cambrex, and ultimately identifying one multipotent stem
cell for clonal propagation. A second lineage was obtained by
isolating a desired multipotent cell from a 9-week old fetal
brain (Christopher L. Brannen and Kiminobu Sugaya, Neuroreport 11, 1123-8 (2000)). The HNSCs so obtained were
maintained in seruni-free medium, and have been demonstrated to have the capability to differentiate into neurons and
glial cells such as astrocytes and dendrocytes.
The following examples are provided to further disclose
the genesis, operation, scope and uses of embodiments of the
present invention. These examples are meant to be instructive, and illustrative, and not to be limiting as to the scope of
invention as claimed herein. These examples are to be considered with the referred to drawings.
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This example demonstrates that transfection of a human
neural stem cell with Hathl results in the transfected cell (or
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its progeny) differentiating into a cell having markers of an
inner ear hair cell (IEHC). Hathl (in humans) and Mathl (in
mice) are basic helix-loop-helix transcription factors (and
homologs of the Drosophila gene atonal) that are expressed in
inner ear sensory epithelia. Since embryonic Mathl-null
mice failed to generate cochlear and vestibular hair cells, it
appears to be required for the generation of inner ear hair cells
(Bermingham N A, Hassan B A, Price S D, Vollrath M A,
Ben-Arie N, Eatock RA, Bellen HJ, Lysakowski A, Zoghbi
HY. 1999. Mathl: An essential gene for the generation of
inner ear hair cells. Science 284 (June 11): 1837-1841). Fate
determination of mammalian IEHC is generally completed
by birth. However, overexpression of Mathl in postnatal rat
cochlear explant cultures resulted in production of extra hair
cells from columnar epithelial cells located outside the sensory epithelium, which normally give rise to inner sulcus
cells. Mathl expression also facilitated conversion of postnatal utricular supporting cells into hair cells (Zheng, G L, Gao
Wq. 2000. Overexpression of Hath 1 induces robust production of extra hair cells in postnatal rat inner ears. Nat Neuroscience June; 3(6):580-6). In vivo, Mathl overexpression
leads to the appearance of immature hair cells in the organ of
Corti and new hair cells adjacent to the organ of Corti in the
interdental cell, inner sulcus, and Hensen cell regions, indicating nonsensory cells in the mature cochlea retain the competence to generate new hair cells after over expression of
Mathl (Kawamoto K, Ishimoto S, Minoda R, Brough D E,
Raphael Y. 2003. Mathl gene transfer generates new cochlear
hair cells in mature guinea pigs in vivo. J Neurosci June 1;
23(11 ):4395-400). Based on the above-summarized work, it
was hypothesized that Hathl may be necessary, and sufficient
as a single introduced gene for expression in a multipotent
neural stem cell, to positively affect differentiation to an
IEHC, or to a cell having characteristics of an IEHC.
A Hathl gene (SEQ ID N0:4) was amplified from the
homo sapiens BAC clone RPl 1-680117 by PCR and then
cloned it into a manimalian expression directional cloning
vector, pcDNAHismax TOPO TA (See FIG. 1; 6xHis tag
disclosed as SEQ ID NO: 16). Upon the insertion of the Hathl
gene expressible sequence into the directional cloning vector,
the expressible sequence was operatively linked to the CMV
promoter, and was also positioned upstream (with regard to
reading) of a polyadenylation transcription termination site.
The clone was confirmed by sequencing of the insert.
An established a non-serum HNSC culture system was
utilized to investigate the differentiation of human neural
stem cells (HNSCs) within a defined condition. (Christopher
L. Brannen and Kiminobu Sugaya, Regeneration and Transplantation, 11:5, 1123-1128 (2000)). The serum-free supplemented growth medium consisted of HAMS-F12 (Gibco,
BRL, Burlington, ON), antibiotic/antimycotic mixture
(1:100, Gibco), B27 (1:50, Gibco), human recombinant
FGF-2 and EGF (20 ng/ml each, Rand D Systems, Minneapolis, Minn.), and heparin (5 ug/ml, Sigma, St. Louis, Mo.).
Cells were maintained in 20 ml of this medium at 37° C. in a
5% co2 humidified incubation chamber.
The manimalian expression vector containing Hathl gene
was transfected into HNSCs by using the Neuroporter Kit
(Gene Therapy Systems, Inc. San Diego, Calif.) and Hath 1
gene expression was confirmed by RT-PCR. These Hathltransfected HNSCs were differentiated for 7 days by the
depletion of mitotic factors (FGF-2, EGF) from the culture
media.Afterthe differentiation the cells were fixed for immunocytochemistry and Electron Microscopy.
The immunocytochemistry revealed the existence of cells
expressing calretinin, a hair cell marker, which were immunoreactive in this culture. These calretinin immunopositive

cells resembled morphology of IEHC. The calretinin expression in the culture was also confirmed by Western blot, which
showed single band specific to calretinin molecular weight
(29 kD). Further electron microscopy analysis of the cells
also showed a typical IEHC morphology. These results indicate that HNSCs transfected with a vector comprising a Hathl
gene differentiate into IEHCs or into cells having characteristics of IEHCs. Comparisons with non-transfected controls
using Western blot and room temperature PCR showed the
presence of Hathl protein and Hathl mRNA in cells transfected with Hathl, but not in the controls.
Thus, embodiments of the present method provide for
improved approaches to obtain IEHCs, or cell having characteristics ofIEHCs, that are derived from HNSCs. Embodiments of the present invention provide a higher percentage of
a population of cells biased, or disposed, to differentiate to
IEHCs, or to cells having characteristics of IEHCs. The
HNSCs utilized in this example are readily and continuously
cultured in serum-free culture medium. Without being limited, in vitro and in vivo studies and trials using cells so
obtained from HNSCs may include electrophysiological
assessment of the cells and investigation of functional recovery after transplantation of the cells into the animal model of
deafness. Positive findings in such pre-clinical studies may
advance the art farther toward treatment of deafness via cell
transplantation therapy using IEHCs produced from HNSCs.
Material and Methods
Hath 1 Transfection
The human Hathl gene (SEQ ID NO: 1) is amplified from
the Homo sapiens BAC clone RPl 1-680117 by PCR, using a
forward primer (5'-TCCGATCCTGAGCGTCCGAGCCTT3', SEQ ID NO: 14) and reverse primer (5'-GCTTCTGTCACCTTCCTAACTTGCC-3', SEQ ID NO: 15). The PCR amplification is conducted in 20 I volumes containing the BAC
clone (100 ng), 1 X amplification buffer, 1 M of each primer,
dNTP Mix (250 M), and Taq DNA Polymerase (2.5 U). The
PCR condition is 95° C. (30"), 59° C. (30"), 72° C. (60") for
35 cycles, with an initial denaturation of 95° C(5') and final
elongation of 72° C. (15'). The PCR amplified fragment is
cloned into a directional pcDNAHismax TOPO TA vector
and the clone is confirmed by sequencing of the insert.
The gene expression ofHathl is assessed by RT-PCR with
the following condition: 95° C. (60"), 56° C. (60"), 72° C.
(60") for 35 cycles, with an initial denaturation of95° C. (5')
and final elongation of72° C. (15'). The Hathl gene is transfected into Human Neural Stem Cells (HNSCs) using the
Neuroporter Kit. The Neuroporter kit utilizes a lipid-based
transfection system for the use with cultured primary neurons, neuronal cell lines, and glial cells. DNA and Neuroporter are used in a ratio of 10 µg DNA/75 µl Neuroporter,
utilizing 37.5 µl per well in a 6-well plate and with total
volumes of 1.5 mL growth media per well. 10 µg of DNA is
added to DNA Diluent to make a total volume of 125 µl; this
is incubated for 5' at room temperature. 75 µl of the Neuroporter Reagent is added to serum-free media to make a final
volume of 125 µ!.These solutions are incubated for 10 minutes to allow Neuroporter/DNA complexes to form, and then
added directly to the HNSCs in a 6-well plate. One day later,
the media is replaced with fresh growth media; one day later,
this is replaced with differentiation media (Basal Medium
Eagle) to induce spontaneous differentiation. The cells are
cultured for 1-2 weeks in a basal differentiation medium
containing Eagle's salts and L-glutamine, which is not
supplemented with FGF-2 or EGF, and is serum-free.
RT-PCR
TRizol reagent is used to extract RNA for RT-PCR and
protein for a Western Blot. 6 µl of the template RNA is added
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to 1x Reaction Mix, 1 µM of each Hathl-specific primer, and
1 µl of the RT-Platinum® Taq Mix. The total volume of the
solution is 20 µ!.The RT-PCR condition is 94° C. (15"), 59°
C. (30"), 72° C. (60") for 40 cycles, with an initial denaturation of 55° C. (30') and 94° C. (5').
Immunocytochemistry
The cells are fixed with 4% paraformaldehyde for 30' at
room temperature, washed in phosphate-buffered saline
(PBS, pH 7.2), then blocked with 3% normal goat serum in
PBS containing 0.05% Triton-XlOO for 1 hour. The cells are
incubated with primary antibody calretinin overnight at 4 ° C.,
with a dilution factor of (1:2000) in PBS containing 0.05%
Triton-XlOO.
Following PBST washing, the cells are incubated with
secondary antibody biotinylated anti-rabbit made in goat in
PBS containing 0.05% Triton-XlOO (PBST), with a dilution
factor of 1:200. This incubation takes 1 hour. The cells are
washed with PBST, and incubated with ABC reagent for 1
hour. Following a PBS wash and staining with DAB for 5-8',
the cells are washed with PBS and distilled water, then stained
with methyl green (5'). The cells are washed with water,
ethanol, and xylene, coverslipped with permount, and ready
for viewing with microscopy.
Western Blot
A Western Blot is performed to assay protein expression.
The protein is extracted with TRizol reagent. 15 µl of the
protein is loaded with the size marker on a PVDF membrane
and run at 200V and 110 mA/gel for 50'. The transfer is run
overnight at 15\7, 1700 mA at 4° C. The membrane is then
washed with PBST 2x10' while rotating, and blocked with
3% milk for 60'. This is washed 2xl 0' with PBST and blocked
with the primary antibody calretinin (1:500) overnight at 4°
C. After washing 3x5' with PBST the membrane is incubated
with the secondary antibody (1 :2000) and shaken for 1 hour.
For detection, 7.5 mL of ECL solution is warmed to room
temperature and 187 .5 µl of solution Bis added to solution A.
7 .5 mL is added to the membrane at RT for 5'. The membrane
is then placed in an x-ray film cassette and exposed as needed
for chemilumescent detection.
Electron Microscopy
Cells were fixed with 3% glutaraldehyde with cacodyate
buffer 0.1 M, and dehydrated with a series of alcohols beginning with 50% up to 100% absolute ethanol followed by
hexamethyldislazne (HMDS). The cultured cells were
allowed to air-dry at room temperature. The specimens were
attached to aluminum stubs using double sided carbon coated
tape, sputter-coated with Platinum and palladium using the
Cressington 208 HR High Resolution Coater. Samples were
viewed with a Jeol 6320F Field Emission Microscope (high
resolution images) and recorded with a digital camera.
Samples were also viewed with the Hitachi Variable pressure
microscope in V-P mode (variable pressure mode) and digitals were captured.
Results
A non-serum HNSC culture system was utilized (Christopher L. Brannen and Kiminobu Sugaya, Regeneration and
Transplantation, 11:5, 1123-1128 (2000)). This culture system provides for the differentiation and expansion ofHNSCs
in vitro in the absence of serum. This system provides for the
observation of differentiation of HNSCs within a defined
condition. These HNSCs have been cultured in a medium
consisting of DMEM/F12, antibiotic-antimycotic mixture
(1:100), B-27 supplement (1:50), human recombinant FGF-2
and EGF (20 ng/ml each), and heparin (5 µg/ml). These cells
have been maintained at 37° C. in a 5% C02 humidified
incubation chamber for more than 3 years in the lab. These
cells are CD133-(a stem cell marker, which is known to be

expressed in stem cells) positive, and GFAP- and ~III-tubu
lin-negative before differentiation. Upon differentiation,
various differentiated cells typically express glial fibrillary
acidic protein (GFAP), or ~III-tubulin, which are glial and
neuronal markers, respectively.
Preferential differentiation of HNSCs into IEHCs can be
induced in vitro by the transfection of Hathl. The human
Hathl gene was amplified from the Homo sapiens BAC clone
RPl 1-680117 by PCR and cloned into a directional pcDNAHismax TOPO TA vector. This was confirmed by sequencing
of the insert. After confirming expression of the gene by
RT-PCR, the Neuroporter kit was utilized to tranfect HNSCs.
These HNSCs were known to be viable and capable of differentiation, aggregrating in neurospheres when multipotent.
Once they began the process of differentiation, they left their
neurospheres. After allowing 7 days for differentiation, these
cells were either stained for hair cell specific markers or
assayed for protein expression. Via immunocytochemistry,
the hair cell marker calretinin was identified on certain cells
(FIG. 2). Via RT-PCR, the expression of this protein XX
clarify which figure or protein? was also verified (FIG. 3).
The presence of the actual protein calretinin on the cell
surface was determined via Western Blot. Seven days for
differentiation was allowed before any analysis of the cells.
Protein was isolated from the cells and calretinin was identified in the cell isolate (FIG. 4).
Using Transmission Electron Microscopy, cells transfected with Hathl and grown to allow for differentiation were
visualized. A subset of the cells exhibited distinct hair-like
projections. These were the actual hairs from the transfected
HNSCs that differentiated into cells having this characteristic
feature ofIEHCs (FIGS. 5 and 6).
Discussion
In order to replace damaged IEHCs, a renewable source
must be created. The HNSCs cultured in serum-free medium
were shown to have the ability to become transfected by
Hathl and then differentiate in vitro into IEHCs, or cells
having characteristics of IEHCs. In the present example,
transfection with and expression of Hathl appears to be an
essential step in the genesis from HNSCs to IEHCs, or cells
having characteristics of IEHCs.
Beforetransfection, HNSCs do not express Hathl. Following transfection with the Neuroporter Kit, they express this
gene in their DNA as verified by RT-PCR. They also produce
the hair cell specific marker calretinin as verified by immuncytochemistry and Western Blot. Furthermore, actual hairs
from the transfected cells can be visualized through electron
microscopy. Thus, characteristics of IEHCs are shown by
these data, and it appears that these cells either are end-stage
IEHCs or are presumptive IEHC cells in that they have at least
two characteristics ofIEHCs.
Cells expressing IEHC markers and differentiating into
cells with hairlike extremities have been generated in this
example. These methods, and the cells produced by the methods of the present invention, as shown in this example,
advance the art of differentiating multipotent stem cells
toward obtaining end-stage neuron-type cells.
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Introduction
A cholinergic deficit is one of the primary features of
Alzheimer's disease (AD), where there is a marked degeneration oflong-projecting axons of cholinergic neurons in the
basal forebrain and target areas in the hippocampus and cerebral cortex. Recent progress in stem cell technologies suggests the probability of using neuroreplacement strategies in
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AD therapy, although several hurdles are implicated: i) is it
possible to generate large numbers of cholinergic neurons
from stem cells; and ii) can long-projecting cholinergic neurons be replaced? Toward improving the ability to conduct
research in the area of cell implantation and replacement
therapies, and toward achieving desired results in later-developed therapies, embodiments of the present invention are
directed to bias human neural stem cells (HNSCs) to differentiate to cells having characteristics of cholinergic neurons
through genetic manipulation of endogenous neural precursors in situ.
The LIM-homeobox gene Lhx8 has been reported to be
crucial for the proper development of basal forebrain cholinergic neurons in mouse (Zhao et al., 2003; Mori et al., 2004).
Lhx8 is expressed in progenitor and postmitotic cells, suggesting that it may have an important role in specification of
neural precursor cells and maintenance of phenotype in differentiating and mature neurons. Furthermore, previous studies using the human neuroblastoma cell line, LA-N-2, have
demonstrated that treatment with retinoic acid (RA) further
enhances cholinergic characteristics of these cells, thus providing a good in vitro model of cholinergic neurons (Crosland, 1996).
The present example utilizes an in vitro assay cell coculture model with plated RA-differentiated LA-N-2 cells
and membrane inserts containing Lhx8-transfected HNSCs,
to assess whether the Lhx8-transfected HNSCs adopt a cholinergic neuronal fate. The rationale behind this co-culture
model is that HNSCs are influenced by intrinsic as well as
extracellular factors in the microenvironment and therefore,
able to respond by differentiating into specific cell types
according to the environmental cues to which they are
exposed. Culture ofRA-differentiated LA-N-2 in basal media
under a serum-free condition, results in the release of factors
to the Lhx8-transfected HNSCs in co-culture. It should be
noted that there is no cell-to-cell contact in this co-culture
system. Thus it is reasonable to assume that any modification
of the cell fate of the genetically modified HNSCs by the
cholinergic-differentiated LA-N-2 cells would come from
membrane permeable endogenous factor(s) released from the
cholinergic-differentiated LA-N-2 cells.
Materials & Method
HNSCs culture: Human NSCs were originally purchased
from Bio Whittaker, Walkersville, Md. These cells have been
expanded and passaged in a serum-free culture medium containing bFGF and EGF in our laboratory for over three years
(Brannen & Sugaya, 2000). The HNSCs were cultured at a
density of50 spheres in 75 cm2 culture flasks (Corning, Cambridge, Mass.) in 20 ml of a serum-free supplemented growth
medium consisting ofHAMS-F12 (Gibco, BRL, Burlington,
ON), antibiotic-antimycotic mixture (1: 100, Gibco ), B27
(1: 50, Gibco ), human recombinant FGF-2 and EGF (20 ng/ml
each, R&D Systems, Minneapolis, Minn.) and heparin (5
µg/ml, Sigma, St. Louis, Mo.) incubated at 37° C. in a 5%
C0 2 humidified incubation chamber (Fisher, Pittsburg, Pa.).
To facilitate optimal growth conditions, HNSCs were sectioned into quarters every 2 weeks and fed by replacing 50%
of the medium every 4-5 days.
LA-N-2 humanneuroblastomaculture: LA-N-2 cells were
obtained from Dr. Jan Blusztajn (Boston University, MA).
The cells were cultured in Leibovitz L-15 medium (Gibco,
BRL, Burlington, ON) containing 10% fetal calf serum and
antibiotic-antimyotic mixture (Gibco) in a humidified incubator at 3 7° C. without C02 . The medium was replaced every
3 days. For treatment with retinoic acid (RA), the cells were
sub-plated at a density of0.5-lxl0 6 cells/plate using 0.25%
trypsin/I mM EDTA (Gibco, BRL) and allowed to attach

overnight. A fresh stock of 4 mM all-trans retinoic acid RA
(Sigma, St. Louis, Mo.) was prepared in 100% ethanol under
amber lighting. RA solution was diluted into culture media
(final concentration. 10- 6 M) and we replaced themedia in the
cells with the RA-containing media. The media was changed
every 48 h during the differentiation of the cells, which was
complete after 7-14 days.
Lhx8 subcloning: The mouse cDNA clone for Lhx8 (SEQ
ID NO: 7, akindgift from Dr Westphal, NIH, Bethesda, Md.)
was inserted into the EcoRl site of the pc DNA 3.1/Zeo mammalian expression vector (Invitrogen). Insertion was subsequently confirmed by restriction digestion and sequence
analysis. This mouse Lhx8 (SEQ ID NO: 7) has high homology to the human sequence (70-80%).
Transfection: HNSCs were placed in 6-well poly-lysine
coated plates and transfected with 4 µg pcDNA 3.1/Lhx8
plasmid using the Neuroporter transfection system (Gene
Therapy Systems, see description in Example 1). Upon the
insertion of the Lhx8 gene expressible sequence into the
directional cloning vector, the expressible sequence was
operatively linked to the CMV promoter, and was also positioned upstream (with regard to reading) ofa polyadenylation
transcription termination site. Lhx8 expression was confirmed after 48 hrs by RT-PCR using primers designed from
the gene cDNA sequence; 5'TGCTGGCATGTCCGCTGTCT'3 (SEQ ID NO: 12, upper primer) and 5'CTGGCTTTGGATGATTGACG'3 (SEQ ID NO: 13, lower
primer). To initiate differentiation, HNSCs were placed in
serum-free basal medium, and allowed to differentiate for
10-15 days in culture.
Co-cultures oftransfected HNSCs and RA-treated LA-N-2
cells: HNSCs (-5xl04 ) transfected with pcDNA 3.1/Lhx8
and non-transfected HNSCs (controls) were transferred into
cell culture inserts with an appropriate pore size and suspended in basal media (in the absence ofFGF-2 and EGF and
without the addition of other extrinsic differentiation factors)
over differentiated LA-N-2 cells plated in 6-well plates. For
immunocytochemical analyses of HNSCs, the culture insert
was removed after 10-20 days of co-culture and the HNSCs
were fixed with 4% paraformaldehyde overnight at 4° C.
Also, transfected HNSCs were cultured without the presence
of differentiated LA-N-2 cells to assess the need for and
effectiveness of the co-culturing.
Immunocytochemistry:
Following fixation, HNSCs were briefly washed 3x5 min
in Phosphate buffered saline (PBS), then blocked with 3%
normal donkey serum in PBS containing 0.05% Tween 20
(PBS-T) and incubated with goat IgG polyclonal anti-human
ChAT (1 :500, Chemicon), mouseigG2b monoclonal anti-human III-tubulin (1: 1000, Sigma) or rabbit anti-human glial
filament protein (GFAP) (1:1000, Sigma) overnight at 4° C.
The corresponding secondary antibodies (donkey anti-goat,
donkey anti-mouse, and donkey anti-rabbit, respectively)
conjugated to rhodamine or FITC (Jackson IR Laboratories,
Inc.) were added for a 2 hr incubation at RT in the dark. Cells
were then washed with PBS (3x5 min) and mounted with
Vectashield with DAPI (Vector Laboratories, CA) for fluorescent microscopic observation. LA-N-2 cells were similarly treated to prepare for microscopic observations.
Results
LA-N-2 cells treated with RA expressed Lhx8, ~III-tubu
lin, and ChAT. This is demonstrated in FI GS. 7A-D. FIG. 7A
shows LA-N-2 cells stained red indicating the presence of
~III-tubulin. FIG. 7B shows LA-N-2 cells stained green indicating the presence of ChAT. FIG. 7C shows LA-N-2 cells
stained green indicating the presence of NGF (blue stain
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indicating counter-staining for nuclei by DAPI). FIG. 7D
(insert) shows non-specific staining for ChAT.
In vitro, HNSCs expressing the LIM homeobox gene,
Lhx8, differentiated into mainly ~III-tubulin and ChAT-positive cells, in co-culture with LA-N-2 cholinergic cells. For the
transfected HNSCs cultured without the presence of differentiated LA-N-2 cells, there was no significant difference
from the non-transfected HNSCs with regard to the number of
cells differentiating to cells having characteristics of cholingeric cells. This demonstrated the need under these experimental conditions for the differentiated LA-N-2 cells (and the
factors released by them).
Non-transfected HNSCs differentiated into mainly ~III
tubulin and GFAP positive cells in co-culture with LA-N-2
cholinergic cells.
With regard to percentage differences between non-transfected cells and transfected cells, in one trial less than two
percent of non-transfected cells, and over 40 percent oftransfected cells, were observed at the end of the trial to have
characteristics of cholinergic neurons.
Conclusions and Comments
Expression of the LIM-homeobox gene Lhx8 triggers
HNSCs to adopt a cholinergic neural lineage. Cells having the
noted characteristics of cholinergic neurons either are cholinergic neurons or presumptive cholinergic neurons in that they
have at least two characteristics of cholinergic neurons.
LA-N-2 cells in co-culture with HNSCs expressing Lhx8,
suggest that the microenvironment is also important for the
differentiation and survival of cholinergic neurons.
The present invention may provide utility by biasing
human neural stem cells through genetically manipulation so
that the cells so manipulated may be used in research, including as cells transplantable, such as in experiments, and therapies, including regarding replacing damaged cholinergic neurans.
As to the efficiency of biasing to a desired cell type, and to
observing cells having characteristics of a desired end-stage
cell type, without being bound to a particular theory, it is
believed that the factors that increase the efficiency of biasing
by transfection include: 1) inherent properties of the cell to be
transfected; 2) inherent efficiency of the selected vector or
method of transfection; 3) relative percentage of cells in
which the introduced nucleic acid sequence enters the
nucleus compared to remains in the cytoplasm; and 4) number
of copies of the nucleic acid sequence that are available for
expression in the cell. Methods of transfection are wellknown in the art, and the use and modification of known
approaches to transfection of a cell with a nucleic acid
sequence to be expressed therein to improve the percentage of
biasing are within the scope of the present invention.
Thus, it is appreciated that in some embodiments of the
present invention, a multipotent stem cell is transfected with
a desired developmental control gene, and the expression of
the gene during in vitro culture biases the differentiation of
that cell to a desired end-stage differentiated cell. In other
embodiments, the multi potent stem cell may be transfected in
vivo with a developmental control gene whose expression
biases transfected cells to differentiate into a desired endstage cell. In any of such embodiments, accessory cells may
provide factors that are needed for, or that assist with, the
differentiation of the transfected cell. These accessory cells,
such as the co-cultured LA-N-2 cells in the above example,
need not be in contact with the transfected cells, demonstrating here that the factors are membrane permeable. These
factors may include the same factor that is expressed by the

transfected gene, or may be other factors known in the art or
later determined to be useful in achieving a desired differentiation.
Also, it is appreciated that multipotent stem cells may be
cultured without an accessory cell, and may receive factors by
direct addition of factors to the culture medium, or such
factors may be released by cells at a site of implantation, or
may be added to a site of implantation.
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EXAMPLE3
Using the same vector formation and transfection methods
as in Example 2, the Human Lxh8 gene (SEQ ID NO: 6) is
transfected into HNSCs. Transfected NHSC cells are cultured
in a first treatment that includes LA-N-2 cells that are treated
with RA and that express both Lhx8 and ChAT. A co-culture
control comprises NHSCs that are not transfected but that are
in the same culture vessel as LA-N-2 that are treated with RA
and that express both Lhx8 and ChAT. For the first treatment
and the co-culture control, HNSC cells are placed in cell
culture inserts with an appropriate pore size and suspended in
basal media (in the absence ofFGF-2 and EGF and without
the addition of other extrinsic differentiation factors) over
differentiated LA-N-2 cells plated in 6-well plates.
Immunochemistry follows the same procedure as in
Example 2 above.
Results indicate that HNSCs transfected with the Human
Lxh8 gene (SEQ ID NO: 6) also are predisposed, or biased, to
differentiate into cells that have characteristics of cholinergic
neurons. Observable results include cells that are positive for
~III-tubulin and ChAT.
EXAMPLE4
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An additional development control gene, Gbxl sequence
(SEQ ID NO: 9), is transfected into HNSCs and is evaluated
as to its capacity to bias HNSCs to differentiate to cholingeric
cells, or to cells having characteristics of cholinergic cells.
The Gbxl cDNA sequence (SEQ ID NO: 9) is inserted into
the enhanced green flouroscent protein (EGFP) vector
pEGFP-Cl ((BDBiosciences Clontech) at the EcoRl site
within the vector's multiple cloning site, which is 3' ofa CMV
promoter and the EGFP gene (See FIG. 8; sequence disclosed
as SEQ ID NO: 17). Further, in that a question remains as to
whether the percentage of biasing is related directly to the
percentage of transfection of cells in population of cells
exposed to a transfecting vector, the human Lhx8 cDNA
(SEQ ID N0:6) independently also is inserted into a second
pEGFP-Cl vector. This allows for visualization of both vectors, each bearing an expressible sequence for a different
developmental control gene, in cells in respective cell populations into which these vectors are transfected.
Culture methods of the HNSCs into which the Gbxl and
the Lhx8 genes are transfected are as described above in
Example 2.
This experiment provides an estimate of the ratio of
HNSCs that become cholinergic neurons based on percent
transfected of the population. Compared to non-transfected
control HNSCs, the transfected cells have characteristics of
the desired end-stage differentiated cell type, that is, a cholinergic neuron.
This demonstrates that a number of development control
genes, particularly transcription factor genes, may be introduced into a HNSC to bias that cell (or its progeny) to differentiate to a cell having the characteristics of a desired endstage differentiated neural cell type.
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EXAMPLES

temperature is used to define the required stringency conditions. If sequences are to be identified that are related and
substantially identical to the probe, rather than identical, then
it is useful to first establish the lowest temperature at which
only homologous hybridization occurs with a particular concentration of salt (e.g., SSC or SSPE).
Then, assuming that 1% mismatching results in a 1° C.
decrease in the Tm, the temperature of the final wash in the
hybridization reaction is reduced accordingly (for example, if
sequences having >95% identity with the probe are sought,
the final wash temperature is decreased by 5° C.). In practice,
the change in Tm can be between 0.5° C. and 1.5° C. per 1%
mismatch. Stringent conditions involve hybridizing at 68° C.
in 5xSSC/5x Denhardt's solution/1.0% SDS, and washing in
0.2xSSC/0.1 % SDS at room temperature. Moderately stringent conditions include washing in 3xSSC at 42° C. The
parameters of salt concentration and temperature can be varied to achieve the optimal level of identity between the probe
and the target nucleic acid. Additional guidance regarding
such conditions is readily available in the art, for example, by
Sambrook et al., 1989, Molecular Cloning, A Laboratory
Manual, Cold Spring Harbor Press, N.Y.; andAusubel et al.
(eds), 1995, Current Protocols in Molecular Biology, (John
Wiley & Sons, N.Y.) at Unit 2.10.
The above-specified sequences are not meant to be limiting. For example, provided herein are additional identified
sequences for Math! (SEQ ID Nos:2 and3), and Hath! (SEQ
ID N0:5). Numerous other similar sequences are known and
searchable at GenBank. Also, the methods and compositions
disclosed and claimed herein for other sequences may be
practiced with Gbxl (SEQ ID N0:9) and sequences similar to
it.
Further, the sequences for introduced genes and polypeptides or proteins expressed by them may also be defined in
terms of homology to one of the sequences provided in the
above examples and discussion. In the context of the present
application, a nucleic acid sequence is "homologous" with
the sequence according to the invention if at least 70%, preferably at least 80%, most preferably at least 90% of its base
composition and base sequence corresponds to the sequence
specified according to the invention. According to the invention, a "homologous protein" is to be understood to comprise
proteins which contain an amino acid sequence at least 70%
of which, preferably at least 80% of which, most preferably at
least 90% of which, corresponds to the amino acid sequence
disclosed in (Gish and States, 1993); wherein corresponds is
to be understood to mean that the corresponding amino acids
are either identical or are mutually homologous amino acids.
The expression "homologous amino acids" denotes those
which have corresponding properties, particularly with
regard to their charge, hydrophobic character, steric properties, etc. Thus, a protein may be from 70% up to less than
100% homologous to any one of the proteins expressed by
one of the disclosed introduced genes.
Homology, sequence similarity or sequence identity of
nucleic acid or amino acid sequences may be determined
conventionally by using known software or computer programs such as the BestFit or Gap pairwise comparison programs (GCG Wisconsin Package, Genetics Computer Group,
575 Science Drive, Madison, Wis. 53711). BestFit uses the
local homology algorithm of Smith and Waterman, Advances
in Applied Mathematics 2: 482-489 (1981 ), to find the best
segment of identity or similarity between two sequences. Gap
performs global alignments: all of one sequence with all of
another similar sequence using the method ofNeedleman and
Wunsch, J. Mo!. Biol. 48:443-453 (1970). When using a
sequence alignment program such as BestFit, to determine

Cell sorting technology is combined with the above-described embodiments of the present invention, particularly
the vectors of Example 4, to improve the yield and selection
of desired cells having the bias to differentiate to a desired
end-stage cell (or having already so differentiated). For
example, not to be limiting, the introduction of genetic marking such as described above, using EFGP, and the use of
Fluorescent Activated Cell Sorter (FACS) techniques is utilized to sort and select cells that have been transfected with
the desired developmental control gene (which is linked to a
marker on the vector). The FACS technology is well known in
the art (See, for example, U.S. patent application No. 20021
0127715 Al.)
Using FACS, HNSCs that are transfected with a vector
bearing both EFGP and either Gbxl or Lhx8 are sorted and
thereby concentrated. This adds to the utility and effectiveness of the biasing by reducing the number and percentage of
cells that are not transfected.
The above examples utilize specific sequences of genes
incorporated into respective vectors and introduced into
HSNCs. However, the present invention is not meant to be
limited to the specifics of these examples.
First, in addition to Math!, Hath!, Lxh8 and Gbxl, other
developmental control genes of interest include Lhx6, IsLl,
Dixl/2 and Mash. Examples of cDNA sequences, and corresponding translated polypeptide and protein sequences, of
these and other developmental control genes are readily
obtainable from the GenBank online database (See
www.ncbi.nlm.nih.qov/entrez/query.fcgi.), and these are
hereby incorporated by reference for that purpose.
Also, as to the nucleic acid sequences comprising the genes
of interest, specific sequences of which are provided in the
above examples and in the above paragraph, it is appreciated
that substantial variation may exist in a nucleic acid sequence
for a gene, yet a polypeptide or protein may nonetheless be
produced in a cell from one of a number of such variant
nucleic acid sequences, wherein such polypeptide or protein
has a desired effect on the cell comparable to a polypeptide or
protein produced from one of the nucleic acid sequences
specified in the above examples. That is, variations may exist
in a nucleic acid sequence for a gene yet the variations nonetheless function effectively when substituted for a nucleic
acid sequence of a specified gene.
Accordingly, embodiments of the present invention also
include and/or employ nucleic acid sequences that hybridize
under stringent hybridization conditions (as defined herein)
to all or a portion of a nucleic acid sequence represented by
any of the SEQ ID Nos. 1-13, or their complements, or to
sequences forlsLl, Dlxl/2, Mash, or their complements. The
hybridizing portion of the hybridizing nucleic acid sequences
is typically at least 15 (e.g., 20, 25, 30, or 50) nucleic acids in
length. The hybridizing portion of the hybridizing nucleic
acid sequence is at least 80%, e.g., at least 95%, or at least
98%, identical to the sequence of a portion or all of a nucleic
acid sequence encoding one of genes identified by the noted
Sequence ID numbers, or one of their complements. Hybridizing nucleic acids of the type described herein can be used,
for example, as a cloning pro be, a primer (e.g., a PCR primer),
or a diagnostic probe, as well as for a gene transfected into a
cell as described in the examples above.
Hybridization of the oligonucleic acid probe to a nucleic
acid sample typically is performed under stringent conditions. Nucleic acid duplex or hybrid stability is expressed as
the melting temperature or Tm, which is the temperature at
which a probe dissociates from a target DNA. This melting
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the degree of sequence homology, similarity or identity, the
default setting may be used, or an appropriate scoring matrix
may be selected to optimize identity, similarity or homology
scores. Similarly, when using a program such as BestFit to
determine sequence identity, similarity or homology between
two different amino acid sequences, the default settings may
be used, or an appropriate scoring matrix, such as blosum45
or blosum80, may be selected to optimize identity, similarity
or homology scores.
Alternatively, as used herein, "percent homology" of two
amino acid sequences or of two nucleic acids is determined
using the algorithm of Karlin andAltschul (Proc. Natl. Acad.
Sci. USA 87:2264-2268, 1990), modified as in Karlin and
Altschul (Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993).
Such an algorithm is incorporated into the NBLAST and
XBLAST programs of Altschul et al. (J. Mo!. Biol. 215:403410, 1990). BLAST nucleic acid searches are performed with
theNBLASTprogram, score=lOO, wordlength=12, to obtain
nucleic acid sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches are performed with the XBLAST program, score=50,
wordlength=3, to obtain amino acid sequences homologous
to a reference polypeptide. To obtain gapped alignments for
comparison purposes, Gapped BLAST is utilized as
described in Altschul et al. (Nucleic Acids Res. 25:33893402, 1997). When utilizing BLAST and Gapped BLAST
programs, the default parameters of the respective programs
(e.g., XBLAST and NBLAST) are used. See www.ncbi.
nlm.nih.gov.
Further, in addition to the homology, as indicated in certain
claims (i.e., for some embodiments), is a requirement that the
homologous or hybridizable nucleic acid sequence or
polypeptide or protein functions analogously to the specified
sequence of which it is homologous or with which it is hybridizable. That is, the homologous or hybridizable variant functions to achieve the same result, i.e., to increase the probability of a transfected cell, or the percentage of a number of cells,
that are biased to differentiate to a cell, or cells, respectively,
having characteristics of a desired end-stage differentiated
cell.
While the transfection into HNSCs in the above examples
uses the Neuroporter approach (Gene Therapy Systems, Inc.
San Diego, Calif.), it is appreciated that any known or laterdeveloped method of introduction of a nucleic acid sequence
may be employed in the methods and systems, and to produce
the compositions, of the present invention. For example, and
not to be limiting, introduction of a nucleic acid sequence
may be effectuated by stable or transient transfection, lipofection by methods other than Neuroporter, calcium phosphate treatment, electroporation, infection with a recombinant viral vector, and the use of vectors comprising a plasmid
construct. Generally and collectively, these methods are considered to be included in the term "means to transfect," in the
term "step for transfecting." Also, the use of the particular
promoter and polyadenylation transcription termination site
are not meant to be limiting, as many promoter and transcription termination sites are known and used routinely in the art.
As to the use of different means to transfect, and in view of
the above discussion of the relative percentage of cells biased
to cells having characteristics of a desired end-stage cell type,
it is appreciated that types of transfection, cells that are transfected, and other factors, including post transfection conditions, affect the percentage of cells ultimately biased. In view
of these factors, and considering the importance of the specific developmental control genes that are introduced to a cell
in certain embodiments of the present invention, in some
embodiments the percentage of transfected cells biased

exceeds 40 percent, in other embodiments the percentage of
transfected cells biased exceeds 50 percent, in other embodiments the percentage of transfected cells biased exceeds 65
percent, and in other embodiments the percentage of transfected cells biased exceeds 70 percent. However, it also is
appreciated that determination of the percentage of cells that
are in fact transfected in a given container of cells may be
difficult to assess, the performance of the present invention in
certain embodiments may be expressed in an alternative manner. That is, in some embodiments of the present invention in
which a number of cells has been exposed to a selected
method or means of transfection for the purpose of introducing a desired developmental control gene (such as Lhx8), the
percentage of total cells that are biased to a desired end-stage
cell type, or to a cell having characteristics of a desired endstage cell type, is at least 35 percent, in other embodiments
such percentage of total cells exceeds 50 percent, and in other
embodiments such percentage of total cells exceeds 70 percent.
Further, it is appreciated that embodiments of the present
invention are described as follows:
1. A neural stem cell, including a human neural stem cell,
comprising an introduced nucleic acid sequence having
an expressible developmental control gene, the expression of said gene being effective to increase the probability of differentiation of said cell to a desired neural
cell type.
2. A neural stem cell, including a human neural stem cell,
comprising an introduced nucleic acid sequence having
an expressible developmental control gene, the expression of said gene being effective to increase the probability of differentiation of said cell to a cell having
characteristics of a cholinergic neuron.
3. A neural stem cell, including a human neural stem cell,
comprising an introduced nucleic acid sequence having
an expressible developmental control gene, the expression of said gene being effective to increase the probability of differentiation of said cell to a cell having
characteristics of an inner ear hair cell.
4. A neural stem cell, including a human neural stem cell,
comprising an introduced nucleic acid sequence having
an expressible developmental control gene, the expression of said gene being effective to increase the probability of differentiation of said cell to a cell having
characteristics of a dopaminergic neuron.
The developmental control gene in the above first description of embodiments of the present invention may be selected
from the group consisting of Math!, Hath!, Lhx8, Gbxl,
Lhx6, IsLl, Dlxl/2, Mash and Nurrl. The developmental
control gene in the above second description of embodiments
of the present invention may be selected from the group
consisting ofLhx8, Gbxl, Lhx6, IsLl, Dlxl/2, and Mash. The
developmental control gene in the above third description of
embodiments of the present invention may be selected from
the group consisting of Math! and Hath!. Finally, the developmental control gene in the above fourth description of
embodiments of the present invention may be Nurrl, Pitx3
(SEQ ID NO: 13) or other later-identified specific genes.
Also, it is appreciated that the present invention, particularly for the genes Math!, Hath!, Lhx8, Gbxl, Lhx6, IsLl,
Dlxl/2, and Mash, may be utilized in potent cells, that is, in
cells that are considered to fall within the definitions of pluripotent, of multipotent, and of progenitor cells (i.e., more
differentiated than multipotent yet capable of limited selfrenewal).
Based on the above examples and disclosure, in view of the
knowledge and skill in the art, it also is appreciated that
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embodiments of the present invention also are used for any
homeobox gene, so that a homeobox gene is transfected to a
stem cell to effect a biasing of the stem cell to differentiate to
a desired end-stage cell, or to a cell having characteristics of
the end-stage cell. The stem cell may be a pluripotent or a
multipotent stem cell; alternatively invention embodiments
transfecting homeobox genes may be practiced with progenitor cells as described herein. Cells so biased by these genes
following the methods of the present invention also are considered to fall within the scope of embodiments of the present
invention.

by virtue of initiating differentiation (or being less self-renewing) may by some opinions therefore not be considered to
be multipotent cells. For the purposes ofthis invention, such
daughter cells, which may be found in culture with the multipotent stem cells from which they arose, are termed "biasable progeny cells."
It is appreciated that embodiments of the present invention
also may be defined and claimed with regard to the polypeptide or protein sequences expressed as a result of the transfections disclosed and discussed above. For example, not to
be limiting, the peptide sequences, disclosed as the translation sequences in the attached Sequence Listing pages, and
their expression in a transfected cell, are used to identify
and/or characterize a characteristic and/or result of embodiments of the present invention. Translation sequences are
obtainable from the respective GenBank database data entries
for cDNAs as described herein, and those database entries are
incorporated by reference for such information.
While a number of embodiments of the present invention
have been shown and described herein in the present context,
such embodiments are provided by way of example only, and
not of limitation. Numerous variations, changes and substitutions will occur to those of skilled in the art without materially departing from the invention herein. For example, the
present invention need not be limited to best mode disclosed
herein, since other applications can equally benefit from the
teachings of the present invention. Also, in the claims, meansplus-function and step-plus-function clauses are intended to
cover the structures and acts, respectively, described herein as
performing the recited function and not only structural
equivalents or act equivalents, but also equivalent structures
or equivalent acts, respectively. Accordingly, all such modifications are intended to be included within the scope of this
invention as defined in the following claims, in accordance
with relevant law as to their interpretation.

10

EXAMPLE6
Nkx.2-5 Biases the Differentiation Toward the
Development of Cardiac Cells
According to another embodiment, transfection with
Nkx2-5 (SEQ ID NO: 12) biases the differentiation toward
the development of cardiac cells. See FIG. 17. Red=human
specific Troponin I, Green= Human cells. Following transfection, multipotent stem cells were cocultured with rat cardiomyocytes that provide environmental signals to allow the
transfected cells to develop properly.
Further, and more generally, embodiments of the present
invention may be practiced by transfecting a stem or a progenitor cell with a nucleic acid sequence comprising a development control gene, so that the transfecting is effective to
bias the cell to differentiate to a desired end-stage cell, or to a
cell having characteristics of the end-stage cell.
Also, it is appreciated that the methods of the present
invention may be applied to the daughter cells of multi potent
cells, which may have begun some stages of differentiation
but are still capable of being biased by transfection of appropriate developmental control genes as described herein, but
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

23

SEQ ID NO 1
LENGTH, 2144
TYPE, DNA
ORGANISM, Mus musculus

<400> SEQUENCE,

1

tcgacccacg cgtccgccca cgcgtccgga tctccgagtg agagggggag ggtcagagga

60

ggaaggaaaa aaaaatcaga ccttgcagaa gagactagga aggtttttgt tgttgttgtt

120

cggggcttat ccccttcgtt gaactgggtt gccagcacct cctctaacac ggcacctccg

180

agccattgca gtgcgatgtc ccgcctgctg catgcagaag agtgggctga ggtaaaagag

240

ttgggggacc accatcgcca tccccagccg caccacgtcc cgccgctgac gccacagcca

300

cctgctaccc tgcaggcgag agaccttccc gt ct ace egg cagaactgtc cctcctggat

360

agcaccgacc cacgcgcctg gctgactccc actttgcagg gcctctgcac ggcacgcgcc

420

gcccagtatc tgctgcattc tcccgagctg ggtgcctccg aggccgcggc gccccgggac

480

gaggctgaca gccagggtga gctggtaagg agaagcggct gtggcggcct cagcaagagc

540

cccgggcccg tcaaagtacg ggaacagctg tgcaagctga agggtggggt tgtagtggac

600

gagcttggct gcagccgcca gcgagcccct tccagcaaac aggtgaatgg ggtacagaag

660

caaaggaggc tggcagcaaa cgcaagggaa cggcgcagga tgcacgggct gaaccacgcc

720
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-continued

ttcgaccagc tgcgcaacgt tatcccgtcc ttcaacaacg acaagaagct gtccaaatat

780

gagaccctac agatggccca gatctacatc aacgctctgt cggagttgct gcagactccc

840

aatgtcggag agcaaccgcc gccgcccaca gcttcctgca aaaatgacca ccatcacctt

900

cgcaccgcct cctcctatga aggaggtgcg ggcgcctctg cggtagctgg ggctcagcca

960

gccccgggag ggggcccgag acctaccccg cccgggcctt gccggactcg cttctcaggc

1020

ccagcttcct ctgggggtta ctcggtgcag ctggacgctt tgcacttccc agccttcgag

1080

gacagggccc taacagcgat gatggcacag aaggacctgt cgccttcgct gcccgggggc

1140

atcctgcagc ctgtacagga ggacaacagc aaaacatctc ccagatccca cagaagtgac

1200

ggagagtttt ccccccactc tcattacagt gactctgatg aggccagtta ggaaggcaac

1260

agctccctga aaactgagac aaccaaatgc ccttcctagc gcgcgggaag ccccgtgaca

1320

aatatccctg caccctttaa tttttggtct gtggtgatcg ttgttagcaa cgacttgact

1380

tcggacggct gcagctcttc caatcccctt cctcctacct tctccttcct ctgtatgtag

1440

atactgtatc attatatgta cctttacgtg gcatcgtttc atggtccatg ctgccaatat

1500

gctgctaaaa tgtcgtatct ctgcctctgg tctgggtttc acttatttta taccttggga

1560

gttcatcctt gcgtgttgcg ctcactcaca aataagggag ttagtcaatg aagttgtttc

1620

cccaactgct tgagacccgc attgggtact ttactgaaca cggactattg tgttgttaaa

1680

atgcaggggc agataagagt atctgtagag cttagacacc aagtgtgtcc agcagtgtgt

1740

ctagcggacc cagaatacac gcacttcatc actggccgct gcgccgcctt gaagaaactc

1800

aactgccaat gcagagcaac ttttgatttt aaaaacagcc actcataatc attaaactct

1860

ttgcaaatgt ttgtttttgc aaatgaaaat taaaaaaaaa catgtagtgt caaaggcatt

1920

tggtcaattt tattttgctt tgttaacatt agaaaagtta tttattattg cgtatttgga

1980

cccatttcta cttaattgcc ttttttttac attttctact cgagatcgtt ttattttgat

2040

ttagcaaatc cagttgccat tgctttatgt atgtatgctc ttttacaaat gataaaataa

2100

actcggaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa

2144

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 2118
TYPE, DNA

ORGANISM, Mus musculus

<400> SEQUENCE, 2

acctggtgtg cgatctccga gtgagagggg gagggtcaga ggaggaagga aaaaaaatca

60

gaccttgcag aagagactag gaaggttttt gttgttgttg ttcggggctt atccccttcg

120

ttgaactggg ttgccagcac ctcctctaac acggcacctc cgagccattg cagtgcgatg

180

tcccgcctgc tgcatgcaga agagtgggct gaggtaaaag agttggggga ccaccatcgc

240

catccccagc cgcaccacgt cccgccgctg acgccacagc cacctgctac cctgcaggcg

300

agagaccttc ccgtctaccc ggcagaactg tccctcctgg atagcaccga cccacgcgcc

360

tggctgactc ccactttgca gggcctctgc acggcacgcg ccgcccagta tctgctgcat

420

tctcccgagc tgggtgcctc cgaggccgcg gcgccccggg acgaggctga cagccagggt

480

gagctggtaa ggagaagcgg ctgtggcggc ctcagcaaga gccccgggcc cgtcaaagta

540

cgggaacagc tgtgcaagct gaagggtggg gttgtagtgg acgagcttgg ctgcagccgc

600

cagcgagccc cttccagcaa acaggtgaat ggggtacaga agcaaaggag gctggcagca

660

aacgcaaggg aacggcgcag gatgcacggg ctgaaccacg ccttcgacca gctgcgcaac

720
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gttatcccgt ccttcaacaa cgacaagaag ctgtccaaat atgagaccct acagatggcc

780

cagatctaca tcaacgctct gtcggagttg ctgcagactc ccaatgtcgg agagcaaccg

840

ccgccgccca cagcttcctg caaaaatgac caccatcacc ttcgcaccgc ctcctcctat

900

gaaggaggtg cgggcgcctc tgcggtagct ggggctcagc cagccccggg agggggcccg

960

agacctaccc cgcccgggcc ttgccggact cgcttctcag gcccagcttc ctctgggggt

1020

tactcggtgc agctggacgc tttgcacttc ccagccttcg aggacagggc cctaacagcg

1080

atgatggcac agaaggacct gtcgccttcg ctgcccgggg gcatcctgca gcctgtacag

1140

gaggacaaca gcaaaacatc tcccagatcc cacagaagtg acggagagtt ttccccccac

1200

tctcattaca gtgactctga tgaggccagt taggaaggca acagctccct gaaaactgag

1260

acaaccaaat gcccttccta gcgcgcggga agccccgtga caaatatccc tgcacccttt

1320

aatttttggt ctgtggtgat cgttgttagc aacgacttga cttcggacgg ctgcagctct

1380

tccaatcccc ttcctcctac cttctccttc ctctgtatgt agatactgta tcattatatg

1440

tacctttacg tggcatcgtt tcatggtcca tgctgccaat atgctgctaa aatgtcgtat

1500

ctctgcctct ggtctgggtt tcacttattt tataccttgg gagttcatcc ttgcgtgttg

1560

cgctcactca caaataaggg agttagtcaa tgaagttgtt tccccaactg cttgagaccc

1620

gcattgggta ctttactgaa cacggactat tgtgttgtta aaatgcaggg gcagataaga

1680

gtatctgtag agcttagaca ccaagtgtgt ccagcagtgt gtctagcgga cccagaatac

1740

acgcacttca tcactggccg ctgcgccgcc ttgaagaaac tcaactgcca atgcagagca

1800

acttttgatt ttaaaaacag ccactcataa tcattaaact ctttgcaaat gtttgttttt

1860

gcaaatgaaa attaaaaaaa aacatgtagt gtcaaaggca tttggtcaat tttattttgc

1920

tttgttaaca ttagaaaagt tatttattat tgcgtatttg gacccatttc tacttaattg

1980

cctttttttt acattttcta ctcgagatcg ttttattttg atttagcaaa tccagttgcc

2040

attgctttat gtatgtatgc tcttttacaa atgataaaat aaactcggaa aaaaaaaaaa

2100

aaaaaaaaaa aaaaaaaa

2118

<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH, 2144
TYPE, DNA
ORGANISM, Mus musculus

<400> SEQUENCE, 3

tcgacccacg cgtccgccca cgcgtccgga tctccgagtg agagggggag ggtcagagga

60

ggaaggaaaa aaaaatcaga ccttgcagaa gagactagga aggtttttgt tgttgttgtt

120

cggggcttat ccccttcgtt gaactgggtt gccagcacct cctctaacac ggcacctccg

180

agccattgca gtgcgatgtc ccgcctgctg catgcagaag agtgggctga ggtaaaagag

240

ttgggggacc accatcgcca tccccagccg caccacgtcc cgccgctgac gccacagcca

300

cctgctaccc tgcaggcgag agaccttccc gtctacccgg cagaactgtc cctcctggat

360

agcaccgacc cacgcgcctg gctgactccc actttgcagg gcctctgcac ggcacgcgcc

420

gcccagtatc tgctgcattc tcccgagctg ggtgcctccg aggccgcggc gccccgggac

480

gaggctgaca gccagggtga gctggtaagg agaagcggct gtggcggcct cagcaagagc

540

cccgggcccg tcaaagtacg ggaacagctg tgcaagctga agggtggggt tgtagtggac

600

gagcttggct gcagccgcca gcgagcccct tccagcaaac aggtgaatgg ggtacagaag

660

caaaggaggc tggcagcaaa cgcaagggaa cggcgcagga tgcacgggct gaaccacgcc

720
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ttcgaccagc tgcgcaacgt tatcccgtcc ttcaacaacg acaagaagct gtccaaatat

780

gagaccctac agatggccca gatctacatc aacgctctgt cggagttgct gcagactccc

840

aatgtcggag agcaaccgcc gccgcccaca gcttcctgca aaaatgacca ccatcacctt

900

cgcaccgcct cctcctatga aggaggtgcg ggcgcctctg cggtagctgg ggctcagcca

960

gccccgggag ggggcccgag acctaccccg cccgggcctt gccggactcg cttctcaggc

1020

ccagcttcct ctgggggtta ctcggtgcag ctggacgctt tgcacttccc agccttcgag

1080

gacagggccc taacagcgat gatggcacag aaggacctgt cgccttcgct gcccgggggc

1140

atcctgcagc ctgtacagga ggacaacagc aaaacatctc ccagatccca cagaagtgac

1200

ggagagtttt ccccccactc tcattacagt gactctgatg aggccagtta ggaaggcaac

1260

agctccctga aaactgagac aaccaaatgc ccttcctagc gcgcgggaag ccccgtgaca

1320

aatatccctg caccctttaa tttttggtct gtggtgatcg ttgttagcaa cgacttgact

1380

tcggacggct gcagctcttc caatcccctt cctcctacct tctccttcct ctgtatgtag

1440

atactgtatc attatatgta cctttacgtg gcatcgtttc atggtccatg ctgccaatat

1500

gctgctaaaa tgtcgtatct ctgcctctgg tctgggtttc acttatttta taccttggga

1560

gttcatcctt gcgtgttgcg ctcactcaca aataagggag ttagtcaatg aagttgtttc

1620

cccaactgct tgagacccgc attgggtact ttactgaaca cggactattg tgttgttaaa

1680

atgcaggggc agataagagt atctgtagag cttagacacc aagtgtgtcc agcagtgtgt

1740

ctagcggacc cagaatacac gcacttcatc actggccgct gcgccgcctt gaagaaactc

1800

aactgccaat gcagagcaac ttttgatttt aaaaacagcc actcataatc attaaactct

1860

ttgcaaatgt ttgtttttgc aaatgaaaat taaaaaaaaa catgtagtgt caaaggcatt

1920

tggtcaattt tattttgctt tgttaacatt agaaaagtta tttattattg cgtatttgga

1980

cccatttcta cttaattgcc ttttttttac attttctact cgagatcgtt ttattttgat

2040

ttagcaaatc cagttgccat tgctttatgt atgtatgctc ttttacaaat gataaaataa

2100

actcggaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa

2144

<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>

SEQ ID NO 4
LENGTH, 1572
TYPE, DNA
ORGANISM, Homo sapiens
FEATURE,
NAME/KEY, modified_base
LOCATION, (1497) .. (1497)
OTHER INFORMATION, a, c,
FEATURE,
NAME/KEY, modified_base
LOCATION, (1504) .. (1504)
OTHER INFORMATION, a, c,
FEATURE,
NAME/KEY, modified_base
LOCATION, (1526) .. (1526)
OTHER INFORMATION, a, c,
FEATURE,
NAME/KEY, modified_base
LOCATION, (1564) .. (1564)
OTHER INFORMATION, a, c,

g, t, unknown or other

g, t, unknown or other

g, t, unknown or other

g, t, unknown or other

<400> SEQUENCE, 4

gtcctctgca cacaagaact tttctcgggg tgtaaaaact ctttgattgg ctgctcgcac

60

gcgcctgccc gcgccctcca ttggctgaga agacacgcga ccggcgcgag gagggggttg

120

ggagaggagc ggggggagac tgagtggcgc gtgccgcttt ttaaaggggc gcagcgcctt

180

cagcaaccgg agaagcatag ttgcacgcga cctggtgtgt gatctccgag tgggtggggg

240
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agggtcgagg agggaaaaaa aaataagacg ttgcagaaga gacccggaaa gggccttttt

300

tttggttgag ctggtgtccc agtgctgcct ccgatcctga gcgtccgagc ctttgcagtg

360

caatgtcccg cctgctgcat gcagaagagt gggctgaagt gaaggagttg ggagaccacc

420

atcgccagcc ccagccgcat catctcccgc aaccgccgcc gccgccgcag ccacctgcaa

480

ctttgcaggc gagagagcat cccgtctacc cgcctgagct gtccctcctg gacagcaccg

540

acccacgcgc ctggctggct cccactttgc agggcatctg cacggcacgc gccgcccagt

600

atttgctaca ttccccggag ctgggtgcct cagaggccgc tgcgccccgg gacgaggtgg

660

acggccgggg ggagctggta aggaggagca gcggcggtgc cagcagcagc aagagccccg

720

ggccggtgaa agtgcgggaa cagctgtgca agctgaaagg cggggtggtg gtagacgagc

780

tgggctgcag ccgccaacgg gccccttcca gcaaacaggt gaatggggtg cagaagcaga

840

gacggctagc agccaacgcc agggagcggc gcaggatgca tgggctgaac cacgccttcg

900

accagctgcg caatgttatc ccgtcgttca acaacgacaa gaagctgtcc aaatatgaga

960

ccctgcagat ggcccaaatc tacatcaacg ccttgtccga gctgctacaa acgcccagcg

1020

gaggggaaca gccaccgccg cctccagcct cctgcaaaag cgaccaccac caccttcgca

1080

ccgcggcctc ctatgaaggg ggcgcgggca acgcgaccgc agctggggct cagcaggctt

1140

ccggagggag ccagcggccg accccgcccg ggagttgccg gactcgcttc tcagccccag

1200

cttctgcggg agggtactcg gtgcagctgg acgctctgca cttctcgact ttcgaggaca

1260

gcgccctgac agcgatgatg gcgcaaaaga atttgtctcc ttctctcccc gggagcatct

1320

tgcagccagt gcaggaggaa aacagcaaaa cttcgcctcg gtcccacaga agcgacgggg

1380

aattttcccc ccattcccat tacagtgact cggatgaggc aagttaggaa ggtgacagaa

1440

gcctgaaaac tgagacagaa acaaaactgc cctttcccag tgcgcgggaa gccccgnggt

1500

taangatccc cgcacccttt aatttnggct ctgcgatggt cgttgtttag caacgacttg

1560

gctncagatg gt

1572

<210>
<211>
<212>
<213>

SEQ ID NO 5
LENGTH, 1065
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 5
atgtcccgcc tgctgcatgc agaagagtgg gctgaagtga aggagttggg agaccaccat

60

cgccagcccc agccgcatca tctcccgcaa ccgccgccgc cgccgcagcc acctgcaact

120

ttgcaggcga gagagcatcc cgtctacccg cctgagctgt ccctcctgga cagcaccgac

180

ccacgcgcct ggctggctcc cactttgcag ggcatctgca cggcacgcgc cgcccagtat

240

ttgctacatt ccccggagct gggtgcctca gaggccgctg cgccccggga cgaggtggac

300

ggccgggggg agctggtaag gaggagcagc ggcggtgcca gcagcagcaa gagccccggg

360

ccggtgaaag tgcgggaaca gctgtgcaag ctgaaaggcg gggtggtggt agacgagctg

420

ggctgcagcc gccaacgggc cccttccagc aaacaggtga atggggtgca gaagcagaga

480

cggctagcag ccaacgccag ggagcggcgc aggatgcatg ggctgaacca cgccttcgac

540

cagctgcgca atgttatccc gtcgttcaac aacgacaaga agctgtccaa atatgagacc

600

ctgcagatgg cccaaatcta catcaacgcc ttgtccgagc tgctacaaac gcccagcgga

660

ggggaacagc caccgccgcc tccagcctcc tgcaaaagcg accaccacca ccttcgcacc

720

gcggcctcct atgaaggggg cgcgggcaac gcgaccgcag ctggggctca gcaggcttcc

780
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ggagggagcc agcggccgac cccgcccggg agttgccgga ctcgcttctc agccccagct

840

tctgcgggag ggtactcggt gcagctggac gctctgcact tctcgacttt cgaggacagc

900

gccctgacag cgatgatggc gcaaaagaat ttgtctcctt ctctccccgg gagcatcttg

960

cagccagtgc aggaggaaaa cagcaaaact tcgcctcggt cccacagaag cgacggggaa

1020

ttttcccccc attcccatta cagtgactcg gatgaggcaa gttag

1065

<210>
<211>
<212>
<213>

SEQ ID NO 6
LENGTH, 2393
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE,

agaggcaaga ggctagcggc tggaccactt gtgctggagt ggtaaagaac tatcatgaat

60

ccatttactg aaagtgtcca tttctgaact caccctaaag aggacaaaca ccgcaaagta

120

gttaaaagtc aggcattcgc gtcggacgtc tgggtttgaa ttctgccctg gcttgactgg

180

aaacgcttcc cctatttctt ccgtagcgga ccgggagagc ttactggcgc tctgcgaacc

240

ggctggaaag aaacaccgag tcactcgtac agactcttgg tcgcagaact tggctttccg

300

ctattggtcc tccagaaccg cttgaaacaa ctggccccag ctggcgcatc agaccgcagt

360

gaggaatgcc gcggggcggg tggcgaaggc agggtctgcc cgccagtgga ttcccgggtg

420

tcccgcgtgg agcaggcttg cccagctggg aagcccatca aacctcagtc ttggcccaca

480

gtgggagaga gaccagtggg tcccagacgg aggccctcgc ccgcttttgg cgacctccac

540

tggcgtgaat aaaagcaccc ctctcttacc ctcagaaact gtgggtagca aggtataaaa

600

cggagtctgg gaccggtaag tcccaaggtg agcccgtata cagctctgcc atctctgagg

660

ggttatgcag attctgagca ggtgtcaggg gctcatgtca gaggagtgcg ggcggactac

720

agccctggcg gccgggagga ctcgcaaagg cgccggggaa gagggactgg tgagccccga

780

gggagcgggg gacgaggact cgtgctcctc ctcggccccg ctgtccccgt cgtcctcgcc

840

ccggtccatg gcctcgggct ccggctgccc tcctggcaag tgtgtgtgca acagttgcgg

900

cctggagatc gtggacaaat accttctcaa ggtgaatgac ctatgctggc atgtccggtg

960

tctctcctgc agtgtttgca gaacctccct aggaaggcac accagctgtt atattaaaga

1020

caaagacatt ttctgcaaac ttgattattt cagaaggtat ggaactcgct gctctcgatg

1080

tgggagacac atccattcta ctgactgggt ccggagagcc aaggggaatg tctatcactt

1140

ggcatgcttt gcctgctttt cctgcaaaag gcaactttcc acaggagagg agtttgcttt

1200

ggtggaagag aaagtcctct gcagagtaca ttatgactgc atgctggata atttaaaaag

1260

agaagtagaa aatgggaatg ggattagtgt ggaaggtgcc ctcctcacag agcaagatgt

1320

taaccatcca aaaccagcaa aaagagctcg gaccagcttt acagcagatc agcttcaggt

1380

tatgcaagca caatttgctc aggacaacaa cccagatgca cagacactcc agaaattggc

1440

agaaaggaca ggcttgagca gacgtgtgat acaggtgtgg tttcagaatt gtagagcacg

1500

ccacaagaaa cacgtcagtc ctaatcactc atcctccacc ccagtcacag cagtcccacc

1560

ctccaggctg tctccaccca tgttagaaga aatggcttat tctgcctacg tgccccaaga

1620

tggaacgatg ttaactgcgc tgcatagtta tatggatgct cattcaccaa caactcttgg

1680

actccagccc ttgttacccc attcaatgac acaactgcca ataagtcata cctaattctt

1740

ttttcaggga tagacttgat taaggatata aatttgtcat ttattatgta taaaatacca

1800

ttgaaaagat attactgtta attttttatt taacacctaa agcatttcca acatcacttt

1860
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gctgcccagg tatgtatcta tagttggcct gcaagacact tttattaatt cttcattttt

1920

tgtaaaactt atgtttacaa gaagaaaaca aatcaaaaca ttttttgtat tgtctggaaa

1980

tagttcactc tagtgtgtat ctgttaattt atttgtcatc aaaagagcac tttgcctaaa

2040

agaaaggact gacaagtgtg caaaatgttt acaatctttt gtgaaattgt agtttatcat

2100

tagtttgtat ctgtaagtta ttgtaataaa tattacctgt attttttgtt atatacaact

2160

ttatactttg aagcttgtat ctgtgaattt gcaactgaaa tttattttgc caatgttttc

2220

tgaatgaact gaataaagct tctgttgtag catgccatgc aaacacatta ttgtgtttgt

2280

ggttgatgaa ttatggctgt aaataacact atagtttaat aagcccacca ttctgagttt

2340

attaaacatt ttccattctt gtgaaaattt caaaaaaaaa aaaaaaaaaa aaa

2393

<210>
<211>
<212>
<213>

SEQ ID NO 7
LENGTH, 1500
TYPE, DNA
ORGANISM, Mus musculus

<400> SEQUENCE, 7

gaattcggca cgagcttcag gaaaagactt ttccccccac tccccctcct ctctgcgagg

60

ttccaccctc tggaaaacac aactttccct ctttttctgg agggacaggc cttagtgtgg

120

ctgagagagg aagaacagtg ggtcagagag tggttacgtc actgtggcct ttttggaaca

180

agacacactg gtggcatcgc tgtcctgcct gttagctttc cttggccttt gggggcggag

240

gaggggacac tgcggacacc cacagcctct gaccctgctg gagctggtat gtgacgagca

300

gccctcgggc catgtattgg aagagcgatc agatgtttgt gtgtaagctg gagggaaagg

360

agatgccgga gctggcggtt ccccgcgaga tgtgccccgg gctcatgtcg gaggagtgcg

420

ggcggcctgc agctggcgcc gggaggaccc gcaaaggctc tggggaagaa ggactggtga

480

atcccgaggg agccggggac gaggactcct gctcctcctc gggcccgctt tccccgtcgt

540

cctcgcccca gtccatggcc tcgggtccga tgtgcccgcc aggcaagtgt gtgtgcagca

600

gctgcggcct ggagattgtg gacaaatacc tcctcaaggt gaatgactta tgctggcatg

660

tccgctgtct ctcctgcagt gtctgcagaa cgtccctggg aaggcacacg agctgctaca

720

ttaaggataa agatattttc tgtaaactcg attacttcag acggtatggg acccgctgtt

780

cccgctgtgg caggcacatc cactcgactg actgggtccg cagggcaaag ggcaacgtgt

840

atcacctggc ctgctttgcc tgcttttctt gcaagaggca gctgtccacg ggagaggagt

900

tcgccttggt ggaggagaag gtcctctgta gagtgcactt tgactgcatg ctggacaatc

960

tgaagagaga agtggagaac ggtaatggga ttagtgtgga aggagccctt ctcacagagc

1020

aagacgtcaa tcatccaaag ccagccaaaa gagctcggac cagcttcaca gccgatcagc

1080

tccaggttat gcaagcacag ttcgctcagg acaacaaccc agatgcacag accctccaga

1140

aactggcaga aaggacaggc ttaagcagac gtgtcataca ggtgtggttt cagaactgca

1200

gggcccgcca taagaaacac gtcagcccaa accattcttc ctcggccccc gtcacagctg

1260

tcccctcctc caggctgtcc ccacccatct tggaagaaat ggcttattct gcctacgacc

1320

cccaggatga cgggatgctg actgcgcact catacttgga tgctcaccaa caactcctgg

1380

actccagccc ttgttacccc atccaatgac ccagctgcca ataagtcata cctaattcct

1440

tctttcaggg atagaaatga ttgaggttat aaacttgtca ttttattatg tataaaaata

1500

<210> SEQ ID NO 8
<211> LENGTH, 751

US 8,080,420 B2

36

35
-continued
<212> TYPE, DNA
<213> ORGANISM, Mus musculus
<400> SEQUENCE, 8

tgttttgtag ctcaccaaca actcctggac tccagccctt gttaccccat ccaatgaccc

60

agctgccaat aagtcatacc taattccttc tttcagggat agaaatgatt gaggttataa

120

acttgtcatt tattatgtat aaaataccat tgagaagata ttaatgttaa ttttttattt

180

aacactcaaa gcatttcgaa catcctctcg ctgcccaggt atgtatctag agttggcctg

240

caagacactt ttattgattc ttcattttgg tttttttttg taaaacttat gtttacaaag

300

aagaaaacaa gtcaaaacat ttttttttgt attgtctgga gatagttggc tcgagtgtgt

360

gtctattaac ttatttgtca ccaaaagagc actttgcctg aaaggcagga ctgatcgtgt

420

gcaaaacgtt tacaatcctt tgtgaaactg tagtttatca ttagtttgta cctgtaagtt

480

attgttataa atattatctg tattttttgt catatacaac tttatacctt gaagcttgta

540

tctgtgaatt tgcaactgaa atttattttg ccagtgtttt cgggacaagc tgaaggcacg

600

tccgttgtag catgccgcgc acacccacgg ggtgcctgca cttggagttc tagctgtaaa

660

taacactcta gtttacaaag cctaccatcc taagttcatt aaacactttg catccttgtg

720

aaagttgctg cccacttctc ttctgtgtgt a

751

<210>
<211>
<212>
<213>

SEQ ID NO 9
LENGTH, 1452
TYPE, DNA
ORGANISM, Mus musculus

<400> SEQUENCE, 9

ggagcaagtg aagcgtaatt tgaggaagat ggatgagtcc ggagggcgac acccccaacc

60

cgcccgcccg ccccctccct ccttatgagc gagagagcgc ggcgccggag ccacactgcg

120

cagagcccgc gccccgccgc cacctcggcc cgcgcgcccg cagcgagcca tgcgtgtccg

180

cgcggggcgc acggcggggc ccgggcagcg ccatgcagag agcggcaggc ggcggcgccc

240

ccgggggcag cggcgggagc agcggcggcc ccggcgccgc cttctccatc gactcgctca

300

tcgggccgcc gccgccgcgc tcgggccacc tgctctacac cggctacccc atgttcatgc

360

cctaccggcc gctcgtgttg ccgcaggcgc tggcccccgc gccgctgccc gccggcctgc

420

cgccgctcgc cccgctcgcc tcgttcgccg gccgcctgag caataccttc tgcgcggggc

480

tgggccaggc ggtgccctcg atggtggcgc tgaccactgc gctgcccagc ttcgcagagc

540

ccccggacgc ctactacggg cccccggagc tcgccgccgc cgccgcctcc accgcctcgc

600

gaagcaaccc ggagcccgcg gcccggcgca ctgacggagc gctggacgct gaggagctgc

660

tgcccgcgcg cgagaaagtg actgaacctc cgccgccccc gcctccgcac ttctctgaga

720

ctttcccgag tctaccggca gaggggaagg tgtacagctc agatgaagag aagctagagc

780

ccccagcagg agacccagca ggcagcgagc aggaggaaga gggctcaggc ggtgacagcg

840

aggacagctt cctggacagt tctgcagggg gcccaggggc tcttctggga cctaaaccga

900

agctaaaggg aagcccgggg actggcgctg aggaggggac accagtggcc acaggggtca

960

ccacgcctgg ggggaaaagc cgaaggcggc gcacagcctt caccagcgag cagcttttgg

1020

agctggagaa ggagtttcac tgcaagaaat acctgagtct gacagagcgc tcccagatcg

1080

cccacgccct caagctcagt gaggtgcagg tgaagatctg gtttcagaac cgccgggcca

1140

agtggaagcg catcaaggct ggcaatgtga gcagtcgttc tggggagccg gtgagaaacc

1200

ccaagattgt agtgcccata cctgtgcacg tcaacaggtt tgctgtgcgc agccagcacc

1260
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aacagatgga gcaaggagcc cggccctgac cgagctcccc ggaccggaag tcacaggatc

1320

tgaacctgtg gccgcccaag actcactggg tactgcagcc tagaggggcc tgttgaaccc

1380

tgctccggga gaggccagcg tattcccggg acacaagact atttggcctg agactgttct

1440

agagacctca gg

1452

<210> SEQ ID NO 10
<211> LENGTH, 1632
<212> TYPE, DNA
<213> ORGANISM, Homo sapiens
<400> SEQUENCE,

10

gacgggtgcg cgggcgggcg gcggcaccat gcagggaagc tgccaggggc cgtgggcagc

60

gccgctttct gccgcccacc tggcgctgtg agactggcgc tgccaccatg ttccccagcc

120

ctgctctcac gcccacgccc ttctcagtca aagacatcct aaacctggaa cagcagcagc

180

gcagcctggc tgccgccgga gagctctctg cccgcctgga ggcgaccctg gcgccctcct

240

cctgcatgct ggccgccttc aagccagagg cctacgctgg gcccgaggcg gctgcgccgg

300

gcctcccaga gctgcgcgca gagctgggcc gcgcgccttc accggccaag tgtgcgtctg

360

cctttcccgc cgcccccgcc ttctatccac gtgcctacag cgaccccgac ccagccaagg

420

accctagagc cgaaaagaaa gagctgtgcg cgctgcagaa ggcggtggag ctggagaaga

480

cagaggcgga caacgcggag cggccccggg cgcgacggcg gaggaagccg cgcgtgctct

540

tctcgcaggc gcaggtctat gagctggagc ggcgcttcaa gcagcagcgg tacctgtcgg

600

cccccgaacg cgaccagctg gccagcgtgc tgaaactcac gtccacgcag gtcaagatct

660

ggttccagaa ccggcgctac aagtgcaagc ggcagcggca ggaccagact ctggagctgg

720

tggggctgcc cccgccgccg ccgccgcctg cccgcaggat cgcggtgcca gtgctggtgc

780

gcgatggcaa gccatgccta ggggactcgg cgccctacgc gcctgcctac ggcgtgggcc

840

tcaatcccta cggttataac gcctaccccg cctatccggg ttacggcggc gcggcctgca

900

gccctggcta cagctgcact gccgcttacc ccgccgggcc ttccccagcg cagccggcca

960

ctgccgccgc caacaacaac ttcgtgaact tcggcgtcgg ggacttgaat gcggttcaga

1020

gccccgggat tccgcagagc aactcgggag tgtccacgct gcatggtatc cgagcctggt

1080

agggaaggga cccgcgtggc gcgaccctga ccgatcccac ctcaacagct ccctgactct

1140

cggggggaga aggggctccc aacatgaccc tgagtcccct ggattttgca ttcactcctg

1200

cggagaccta ggaacttttt ctgtcccacg cgcgtttgtt cttgcgcacg ggagagtttg

1260

tggcggcgat tatgcagcgt gcaatgagtg atcctgcagc ctggtgtctt agctgtcccc

1320

ccaggagtgc cctccgagag tccatgggca cccccggttg gaactgggac tgagctcggg

1380

cacgcagggc ctgagatctg gccgcccatt ccgcgagcca gggccgggcg cccgggcctt

1440

tgctatctcg ccgtcgcccg cccacgcacc cacccgtatt tatgttttta cctattgctg

1500

taagaaatga cgatcccctt cccattaaag agagtgcgtt gaaaaaaaaa aaaaaaaaaa

1560

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

1620

aaaaaaaaaa aa

1632

<210>
<211>
<212>
<213>

SEQ ID NO 11
LENGTH, 1406
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 11
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40

39
-continued
gagcgcccga gcggagaggc ggcccgggag caggggggcg gcccccactc cggccgggtg

60

cccggcccct ggcccctgcc tgccctctag atcgccgccg cagccgccgc tactgggagt

120

ctgcctgttg caggacgcac tagccctccc tccatggagt tcggcctgct cagcgaggca

180

gaggcccgga gccctgccct gtcgctgtca gacgctggca ctccgcaccc ccagctccca

240

gagcacggct gcaagggcca ggagcacagc gactcagaaa aggcctcggc ttcgctgccc

300

ggcggctccc cagaggacgg ttcgctgaaa aagaagcagc ggcggcagcg cacgcacttc

360

accagccagc agctacagga gctagaggcg accttccaga ggaaccgcta ccccgacatg

420

agcacgcgcg aggagattgc cgtgtggacc aacctcaccg aggcccgcgt gcgggtgtgg

480

ttcaagaacc ggcgcgccaa atggcggaag cgcgagcgca gccagcaggc cgagctatgc

540

aaaggcagct tcgcggcgcc gctcgggggg ctggtgccgc cctacgagga ggtgtacccc

600

ggctactcgt acggcaactg gccgcccaag gctcttgccc cgccgctcgc cgccaagacc

660

tttccattcg ccttcaactc ggtcaacgtg gggcctctgg cttcgcagcc cgtcttctcg

720

ccacccagct ccatcgccgc ctccatggtg ccctccgccg cggctgcccc gggcaccgtg

780

ccagggcctg gggccctgca gggcctgggc gggggccccc ccgggctggc tccggccgcc

840

gtgtcctccg gggccgtgtc ctgcccttat gcctcggccg ccgccgccgc cgcggctgcc

900

gcctcttccc cctacgtcta tcgggacccg tgtaactcga gcctggccag cctgcggctc

960

aaagccaaac agcacgcctc cttcagctac cccgctgtgc acgggccgcc cccggcagcc

1020

aaccttagtc cgtgccagta cgccgtggaa aggcccgtat gagcggcccc gcccgtagat

1080

catccccgag ggcgggggca acgattcaca gcctccgcgg actggggtca ttttgactgg

1140

cttgctcccg ccccagggtc tgaaaggggt gtttgggcag ctggggggca ccggctcagg

1200

agagggcctt cccctcccag ccctgagggg tggactaggc cctacacaca gaccgcgccc

1260

ctgggactaa agccaggaac agggaccagc tccccggggg ccaactcacc cttggcccat

1320

cccgccttct ccaggcttcc cctccctcgt tttcaaagat aaatgaaata aacgtgcgcg

1380

gactgtcaaa aaaaaaaaaa aaaaaa

1406

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 12
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 12
tgctggcatg tccgctgtct

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 13
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 13
ctggctttgg atgattgacg

<210>
<211>
<212>
<213>

SEQ ID NO 14
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence

20

US 8,080,420 B2
41

42
-continued

<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 14
tccgatcctg agcgtccgag cctt

<210>
<211>
<212>
<213>
<220>
<223>

24

SEQ ID NO 15
LENGTH, 25
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 15
25

gcttctgtca ccttcctaac ttgcc

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 16
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
6xHis tag

<400> SEQUENCE, 16
His His His His His His
1
5

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 17
LENGTH, 94
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polynucleotide

<400> SEQUENCE, 17
tacaagtccg gactcagatc tcgagctcaa gcttcgaatt ctgcagtcga cggtaccgcg

60

ggcccgggat ccaccggatc tagataactg atca

94

<210>
<211>
<212>
<213>

SEQ ID NO 18
LENGTH, 351
TYPE, PRT
ORGANISM, Mus musculus

<400> SEQUENCE,

18

Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu
1
5
10
15
Gly Asp His His Arg His Pro Gln Pro His His Val Pro Pro Leu Thr
20
25
30
Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Asp Leu Pro Val Tyr Pro
35
40
45
Ala Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp Leu Thr
50
55
60
Pro Thr Leu Gln Gly Leu Cys Thr Ala Arg Ala Ala Gln Tyr Leu Leu
65
70
75
80
His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg Asp Glu

85

90

95

Ala Asp Ser Gln Gly Glu Leu Val Arg Arg Ser Gly Cys Gly Gly Leu
100
105
110
Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu Cys Lys Leu
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43
-continued
115

120

125

Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg Gln Arg Ala
130
135
140
Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg Arg Leu Ala
145
150
155
160
Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn His Ala Phe
165
170
175
Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp Lys Lys Leu
180
185
190
Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile Asn Ala Leu
195
200
205
Ser Glu Leu Leu Gln Thr Pro Asn Val Gly Glu Gln Pro Pro Pro Pro
210
215
220
Thr Ala Ser Cys Lys Asn Asp His His His Leu Arg Thr Ala Ser Ser
225
230
235
240
Tyr Glu Gly Gly Ala Gly Ala Ser Ala Val Ala Gly Ala Gln Pro Ala
245
250
255
Pro Gly Gly Gly Pro Arg Pro Thr Pro Pro Gly Pro Cys Arg Thr Arg
260
265
270
Phe Ser Gly Pro Ala Ser Ser Gly Gly Tyr Ser Val Gln Leu Asp Ala
275
280
285
Leu His Phe Pro Ala Phe Glu Asp Arg Ala Leu Thr Ala Met Met Ala
290
295
300
Gln Lys Asp Leu Ser Pro Ser Leu Pro Gly Gly Ile Leu Gln Pro Val
305
310
315
320
Gln Glu Asp Asn Ser Lys Thr Ser Pro Arg Ser His Arg Ser Asp Gly
325
330
335
Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu Ala Ser
340
345
350

<210>
<211>
<212>
<213>

SEQ ID NO 19
LENGTH, 351
TYPE, PRT
ORGANISM, Mus musculus

<400> SEQUENCE, 19
Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu
1
5
10
15
Gly Asp His His Arg His Pro Gln Pro His His Val Pro Pro Leu Thr
20
25
30
Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Asp Leu Pro Val Tyr Pro
35
40
45
Ala Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp Leu Thr
50
55
60
Pro Thr Leu Gln Gly Leu Cys Thr Ala Arg Ala Ala Gln Tyr Leu Leu
65
70
75
80
His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg Asp Glu
85
90
95
Ala Asp Ser Gln Gly Glu Leu Val Arg Arg Ser Gly Cys Gly Gly Leu
100
105
110
Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu Cys Lys Leu
115
120
125
Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg Gln Arg Ala
130
135
140
Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg Arg Leu Ala
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46

45
-continued
145

150

155

160

Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn His Ala Phe
165
170
175
Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp Lys Lys Leu
180
185
190
Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile Asn Ala Leu
195
200
205
Ser Glu Leu Leu Gln Thr Pro Asn Val Gly Glu Gln Pro Pro Pro Pro
210
215
220
Thr Ala Ser Cys Lys Asn Asp His His His Leu Arg Thr Ala Ser Ser
225
230
235
240
Tyr Glu Gly Gly Ala Gly Ala Ser Ala Val Ala Gly Ala Gln Pro Ala
245
250
255
Pro Gly Gly Gly Pro Arg Pro Thr Pro Pro Gly Pro Cys Arg Thr Arg
260
265
270
Phe Ser Gly Pro Ala Ser Ser Gly Gly Tyr Ser Val Gln Leu Asp Ala
275
280
285
Leu His Phe Pro Ala Phe Glu Asp Arg Ala Leu Thr Ala Met Met Ala
290
295
300
Gln Lys Asp Leu Ser Pro Ser Leu Pro Gly Gly Ile Leu Gln Pro Val
305
310
315
320
Gln Glu Asp Asn Ser Lys Thr Ser Pro Arg Ser His Arg Ser Asp Gly
325
330
335
Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu Ala Ser
340
345
350

<210>
<211>
<212>
<213>

SEQ ID NO 20
LENGTH, 354
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 20
Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu
1
5
10
15
Gly Asp His His Arg Gln Pro Gln Pro His His Leu Pro Gln Pro Pro
20
25
30
Pro Pro Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Glu His Pro Val
35
40
45
Tyr Pro Pro Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp
50
55
60
Leu Ala Pro Thr Leu Gln Gly Ile Cys Thr Ala Arg Ala Ala Gln Tyr
65
70
75
80
Leu Leu His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg
85
90
95
Asp Glu Val Asp Gly Arg Gly Glu Leu Val Arg Arg Ser Ser Gly Gly
100
105
110
Ala Ser Ser Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu
115
120
125
Cys Lys Leu Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg
130
135
140
Gln Arg Ala Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg
145
150
155
160
Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn
165
170
175
His Ala Phe Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp

US 8,080,420 B2

47

48
-continued

180

185

190

Lys Lys Leu Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile
195
200
205
Asn Ala Leu Ser Glu Leu Leu Gln Thr Pro Ser Gly Gly Glu Gln Pro
210
215
220
Pro Pro Pro Pro Ala Ser Cys Lys Ser Asp His His His Leu Arg Thr
225
230
235
240
Ala Ala Ser Tyr Glu Gly Gly Ala Gly Asn Ala Thr Ala Ala Gly Ala
245
250
255
Gln Gln Ala Ser Gly Gly Ser Gln Arg Pro Thr Pro Pro Gly Ser Cys
260
265
270
Arg Thr Arg Phe Ser Ala Pro Ala Ser Ala Gly Gly Tyr Ser Val Gln
275
280
285
Leu Asp Ala Leu His Phe Ser Thr Phe Glu Asp Ser Ala Leu Thr Ala
290
295
300
Met Met Ala Gln Lys Asn Leu Ser Pro Ser Leu Pro Gly Ser Ile Leu
305
310
315
320
Gln Pro Val Gln Glu Glu Asn Ser Lys Thr Ser Pro Arg Ser His Arg
325
330
335
Ser Asp Gly Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu
340
345
350
Ala Ser

<210>
<211>
<212>
<213>

SEQ ID NO 21
LENGTH, 354
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 21
Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu
1
5
10
15
Gly Asp His His Arg Gln Pro Gln Pro His His Leu Pro Gln Pro Pro
20
25
30
Pro Pro Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Glu His Pro Val
35
40
45
Tyr Pro Pro Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp
50
55
60
Leu Ala Pro Thr Leu Gln Gly Ile Cys Thr Ala Arg Ala Ala Gln Tyr
65
70
75
80
Leu Leu His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg
85
90
95
Asp Glu Val Asp Gly Arg Gly Glu Leu Val Arg Arg Ser Ser Gly Gly
100
105
110
Ala Ser Ser Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu
115
120
125
Cys Lys Leu Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg
130
135
140
Gln Arg Ala Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg
145
150
155
160
Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn
165
170
175
His Ala Phe Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp
180
185
190
Lys Lys Leu Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile
195
200
205

US 8,080,420 B2

50

49
-continued
Asn Ala Leu Ser Glu Leu Leu Gln Thr Pro Ser Gly Gly Glu Gln Pro
210
215
220
Pro Pro Pro Pro Ala Ser Cys Lys Ser Asp His His His Leu Arg Thr
225
230
235
240
Ala Ala Ser Tyr Glu Gly Gly Ala Gly Asn Ala Thr Ala Ala Gly Ala
245
250
255
Gln Gln Ala Ser Gly Gly Ser Gln Arg Pro Thr Pro Pro Gly Ser Cys
260
265
270
Arg Thr Arg Phe Ser Ala Pro Ala Ser Ala Gly Gly Tyr Ser Val Gln
275
280
285
Leu Asp Ala Leu His Phe Ser Thr Phe Glu Asp Ser Ala Leu Thr Ala
290
295
300
Met Met Ala Gln Lys Asn Leu Ser Pro Ser Leu Pro Gly Ser Ile Leu
305
310
315
320
Gln Pro Val Gln Glu Glu Asn Ser Lys Thr Ser Pro Arg Ser His Arg
325
330
335
Ser Asp Gly Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu
340
345
350
Ala Ser

<210>
<211>
<212>
<213>

SEQ ID NO 22
LENGTH, 356
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 22
Met Gln Ile Leu Ser Arg Cys Gln Gly Leu Met Ser Glu Glu Cys Gly
1
5
10
15
Arg Thr Thr Ala Leu Ala Ala Gly Arg Thr Arg Lys Gly Ala Gly Glu
20
25
30
Glu Gly Leu Val Ser Pro Glu Gly Ala Gly Asp Glu Asp Ser Cys Ser
35
40
45
Ser Ser Ala Pro Leu Ser Pro Ser Ser Ser Pro Arg Ser Met Ala Ser
50
55
60

Gly Ser Gly Cys Pro Pro Gly Lys Cys Val Cys Asn Ser Cys Gly Leu
65
70
75
80
Glu Ile Val Asp Lys Tyr Leu Leu Lys Val Asn Asp Leu Cys Trp His
85
90
95
Val Arg Cys Leu Ser Cys Ser Val Cys Arg Thr Ser Leu Gly Arg His
100
105
110
Thr Ser Cys Tyr Ile Lys Asp Lys Asp Ile Phe Cys Lys Leu Asp Tyr
115
120
125
Phe Arg Arg Tyr Gly Thr Arg Cys Ser Arg Cys Gly Arg His Ile His
130
135
140
Ser Thr Asp Trp Val Arg Arg Ala Lys Gly Asn Val Tyr His Leu Ala
145
150
155
160
Cys Phe Ala Cys Phe Ser Cys Lys Arg Gln Leu Ser Thr Gly Glu Glu
165
170
175
Phe Ala Leu Val Glu Glu Lys Val Leu Cys Arg Val His Tyr Asp Cys
180
185
190
Met Leu Asp Asn Leu Lys Arg Glu Val Glu Asn Gly Asn Gly Ile Ser
195
200
205
Val Glu Gly Ala Leu Leu Thr Glu Gln Asp Val Asn His Pro Lys Pro
210
215
220
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51
-continued
Ala Lys Arg Ala Arg Thr Ser Phe Thr Ala Asp Gln Leu Gln Val Met
225
230
235
240
Gln Ala Gln Phe Ala Gln Asp Asn Asn Pro Asp Ala Gln Thr Leu Gln
245
250
255
Lys Leu Ala Glu Arg Thr Gly Leu Ser Arg Arg Val Ile Gln Val Trp
260
265
270
Phe Gln Asn Cys Arg Ala Arg His Lys Lys His Val Ser Pro Asn His
275
280
285
Ser Ser Ser Thr Pro Val Thr Ala Val Pro Pro Ser Arg Leu Ser Pro
290
295
300
Pro Met Leu Glu Glu Met Ala Tyr Ser Ala Tyr Val Pro Gln Asp Gly
305
310
315
320
Thr Met Leu Thr Ala Leu His Ser Tyr Met Asp Ala His Ser Pro Thr
325
330
335
Thr Leu Gly Leu Gln Pro Leu Leu Pro His Ser Met Thr Gln Leu Pro
340
345
350
Ile Ser His Thr
355

<210>
<211>
<212>
<213>

SEQ ID NO 23
LENGTH, 365
TYPE, PRT
ORGANISM, Mus musculus

<400> SEQUENCE,

23

Met Tyr Trp Lys Ser Asp Gln Met Phe Val Cys Lys Leu Glu Gly Lys
1
5
10
15
Glu Met Pro Glu Leu Ala Val Pro Arg Glu Met Cys Pro Gly Leu Met
20
25
30
Ser Glu Glu Cys Gly Arg Pro Ala Ala Gly Ala Gly Arg Thr Arg Lys
35
40
45
Gly Ser Gly Glu Glu Gly Leu Val Asn Pro Glu Gly Ala Gly Asp Glu
50
55
60
Asp Ser Cys Ser Ser Ser Gly Pro Leu Ser Pro Ser Ser Ser Pro Gln
65
70
75
80
Ser Met Ala Ser Gly Pro Met Cys Pro Pro Gly Lys Cys Val Cys Ser
85
90
95
Ser Cys Gly Leu Glu Ile Val Asp Lys Tyr Leu Leu Lys Val Asn Asp
100
105
110
Leu Cys Trp His Val Arg Cys Leu Ser Cys Ser Val Cys Arg Thr Ser
115
120
125
Leu Gly Arg His Thr Ser Cys Tyr Ile Lys Asp Lys Asp Ile Phe Cys
130
135
140
Lys Leu Asp Tyr Phe Arg Arg Tyr Gly Thr Arg Cys Ser Arg Cys Gly
145
150
155
160
Arg His Ile His Ser Thr Asp Trp Val Arg Arg Ala Lys Gly Asn Val
165
170
175
Tyr His Leu Ala Cys Phe Ala Cys Phe Ser Cys Lys Arg Gln Leu Ser
180
185
190
Thr Gly Glu Glu Phe Ala Leu Val Glu Glu Lys Val Leu Cys Arg Val
195
200
205
His Phe Asp Cys Met Leu Asp Asn Leu Lys Arg Glu Val Glu Asn Gly
210
215
220

Asn Gly Ile Ser Val Glu Gly Ala Leu Leu Thr Glu Gln Asp Val Asn
225
230
235
240
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53
-continued
His Pro Lys Pro Ala Lys Arg Ala Arg Thr Ser Phe Thr Ala Asp Gln
245

250

255

Leu Gln Val Met Gln Ala Gln Phe Ala Gln Asp Asn Asn Pro Asp Ala
260

265

270

Gln Thr Leu Gln Lys Leu Ala Glu Arg Thr Gly Leu Ser Arg Arg Val
275

280

285

Ile Gln Val Trp Phe Gln Asn Cys Arg Ala Arg His Lys Lys His Val
290

295

300

Ser Pro Asn His Ser Ser Ser Ala Pro Val Thr Ala Val Pro Ser Ser
305

310

315

320

Arg Leu Ser Pro Pro Ile Leu Glu Glu Met Ala Tyr Ser Ala Tyr Asp
325

330

335

Pro Gln Asp Asp Gly Met Leu Thr Ala His Ser Tyr Leu Asp Ala His
340

345

350

Gln Gln Leu Leu Asp Ser Ser Pro Cys Tyr Pro Ile Gln
355

360

365

What is claimed is:
from the group consisting of SEQ ID NOs:l, 2 and3, or
a sequence that encodes SEQ ID NO. 19, and a transcrip1. A method of biasing differentiation of a neural stem cell 25
tion termination site,
comprising introducing a nucleic acid sequence into the neuwherein expression of the expressible sequence in one or
ral stem cell, in vitro, the nucleic acid sequence comprising a
more cells transfected, in vitro, with a copy of the nucleic acid
promoter operatively linked to an expressible sequence comsequence is effective to bias the one or more cells to a desired
prising a sequence selected from the group consisting of SEQ
end-stage cell type, or to an presumptive end-stage cell havID NOs: 1, 2 and 3, or a sequence that encodes SEQ ID NO. 3o ing characteristics of the desired end-stage cell type, in vitro,
19, the nucleic acid sequence comprising a transcription terwherein the desired end-stage cell type is an Inner Ear Hair
mination site, wherein expression of the expressible sequence
Cell (IEHC).
is effective to bias the neural stem cell to a desired end-stage
7. The method of claim 6, the population of cells additioncell type, or to a presumptive end-stage cell having characally comprising one or more biasable progeny cells.
8. The method of claim 6, the neural stem cells comprising
teristics of the desired end-stage cell type, in vitro, wherein 35
human neural stem cells.
the desired end-stage cell type is an Inner Ear Hair Cell
9. An isolated cell produced by the method of claim 8.
(IEHC).
10. A method of modifying a neural stem cell to bias
2. An isolated cell produced by the method of claim 1.
differentiation of said neural stem cell toward a desired end3. An isolated cell produced by the method of claim 1.
40 stage differentiated cell in vitro comprising the step of:
4. A method of biasing differentiation of a neural stem cell
introducing a nucleic acid sequence into said neural stem
in vitro comprising:
cell, in vitro, the nucleic acid sequence comprising a
a. providing the neural stem cell;
promoter operatively linked to a developmental control
b. preparing a nucleic acid sequence comprising a progene selected from the group consisting of SEQ ID
moter operatively linked to an expressible sequence that 45
NOs:l, 2, and3, ora sequence that encodes SEQ ID NO.
comprises a sequence selected from the group consisting
19;
of SEQ ID NOs:l, 2 and 3, or a sequence that encodes
wherein expression of the developmental biasing gene
SEQ ID NO. 19, the nucleic acid sequence comprising a
increases probability of said potent cell to differentiate into a
transcription termination site; and
desired end-stage differentiated cell, in vitro, wherein the
c. transfecting said neural stem cell with said nucleic acid
50 desired end-stage cell type is an Inner Ear Hair Cell (IEHC).
sequence, in vitro,;
11. A method of modifying a neural stem cell to bias
wherein expression of the expressible sequence results in
differentiation of said neural stem cell toward a desired endbiasing the neural stem cell to a desired end-stage cell type, or
stage differentiated cell in vitro comprising the step of:
to an presumptive end-stage cell having characteristics of the
introducing a nucleic acid sequence into said neural stem
desired end-stage cell type, in vitro, wherein the desired end- 55
cell, in vitro, the nucleic acid sequence comprising a
stage cell type is an Inner Ear Hair Cell (IEHC).
promoter operatively linked to a developmental control
5. An isolated cell produced by the method of claim 4.
gene selected from the group consisting of SEQ ID
6. A method of biasing differentiation of one or more cells
NOs: 1, 2 and 3, or a sequence that encodes SEQ ID NO.
in a population of cells comprising neural stem cells, com19;
prising:
60 wherein expression of the developmental biasing gene
d. providing the population of cells in a vessel;
increases probability of said potent cell to differentiate into a
e. adding to the vessel one or more copies of a nucleic acid
desired end-stage differentiated cell, in vitro, wherein the
sequence, each nucleic acid sequence comprising a prodesired end-stage cell type is an Inner Ear Hair Cell (IEHC).
moter operatively linked to a expressible sequence, the
expressible sequence comprising a sequence selected
* * * * *

